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ABSTRACT

GIZELLE SUSETTE BAKER. Cancer Dose-Response Modeling of Low Dose
Radiation Exposure. (Under the direction of DAVID G. HOEL, Ph.D.).

Many late effects from exposure to ionizing radiation, including cancers, have

been described in the literature. The identification and quantification of radiation-induced
health effects is an important and complex issue. Recommendations for radiation safety
and protection from the International Commission on Radiological Protection are made
using a linear no threshold risk model on epidemiological data. A major obstacle in this
process is the limited availability of data to directly measure the health effects of
radiation on human populations.

One way to circumvent this problem

IS

to use

experimental data from laboratory animals and extrapolate across species to man.
The cancer incidence and mortality data from the Japanese atomic bomb survivors

was adjusted for uncertainty that exists in the dose estimates, systematic error in the
neutron dose estimates, and a dose-dependent relative biological effectiveness.

A

threshold term was included in the -Poisson regression model as a surrogate for
nonlinearity in the dose response curve. The research suggests that the threshold
improves the fit of the model for the solid tumor incidence, as well as the leukemia
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incidence and mortality data (although the mortality data was not a significant
improvement).

In our study, B6CF 1 mice were used to assess the shape of the dose response
curve and the effects of fractionation at low doses. The Cox proportional hazards model
was used to as an empirical model, while the two-stage clonal expansion model was used
as the biologically based cancer model in which infonnation on the carcinogenesis
process is incorporated into the model. The two models resulted in similar descriptions

of the dose response curves, cancer risks, neutron relative biological effectiveness and
dose rate effectiveness factor associated with exposure to ionizing radiation.

The

analyses indicate that the dose response curve appears linear in the low dose region, and
fractionation reduces the effectiveness of gamma exposure while increasing the
effectiveness of neutron exposure.

-lV-

1. Introduction

1. INTRODUCTION
The derivation of cancer risks from low dose and low dose rate exposures to
ionizing radiation is important in the setting of standards for radiological protection. The
problem is there are only a few human populations exposed at low to moderate dose rates
in which direct estimates of cancer risk can be calculated.

Therefore, most of the

infonnation available today about cancer risks in human populations following exposure
to ionizing radiation corne from extrapolating high dose, high dose rate studies.

The

Japanese atomic bomb survivor Life Span Study (LSS) data is a major source of a data
for determining risk estimates of radiation-induces cancers (Fry and Sinclair 1987;Vaeth
and Stram 1989). The issue that arises when modeling cancer risks at low doses using
epidemiological methods is that it is nearly impossible to observe, with statistical
confidence an increased cancer incidence due to exposure (National Council on Radiation
Protection and Measurements 2001).

Since error in dosimetry impact both the risk

estimates and radiation protection standards, it is important to consider them in the
modeling of this data.
The radiation exposures that resulted from the two atomic bombs dropped in
Japan are considered mixed exposures, since the survivors were exposed to a
combination of gamma and neutron radiation.

The uranium bomb used in Hiroshima

generated a substantially higher dose of neutron as compared to the minimal neutrons
delivered by the plutonium bomb in Nagasaki (Hollingsworth 1986;Roberts 1987). The
difference in the bombs is important in that there is an inverse relationship between the
risk coefficients for gamma rays and neutrons (Kellerer and Nekolla 1997).

This

relationship is obvious in that the excess mortality is made up of a neutron and gamma
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ray component; and as the attribution due to neutrons increases the attribution of photons
decreases. In previous analyses of for Radiation Effects Research Foundation (RERF)
reports on the atomic bomb survivors, and for radiation protection purposes a linear dose
response relationship has been assumed for low dose exposures of neutrons and photons.
In recent years the possibility of non-linearities in the low dose region of the dose
response curve has been a topic that has generated a lot of interest. Threshold models
have been used as a surrogate for non-linearities, and in an analysis using the unadjusted
dosimetry system 1986 (DS86) dose values, a threshold modeled significantly improved
the fit of the model to the leukemia incidence data (Hoel and Li 1998).

It was

hypothesized that the improvement in fit with a threshold term could simply be the
artifact of the errors associated with the dose estimates (Little 1999). Therefore, it will be
important to see if the findings hold true after adjustments are made to the dose estimates.
It is recognized that both systematic errors and uncertainty in the dose estimates
may alter the shape of the dose response relationship and in effect the evidence for
curvature in the dose response curve.

The problem with the uncertainty in the dose

estimates, also known as random error in the dosimetry, has been investigated (Gilbert
1984;lablon S. 1971) and many papers have been published on the methods that have
been developed to account for random error in the total dose (Little and Muirhead 1996,
1997;Pierce et al. 1990). More recently, these methods have been modified to account
for the error in the two subcomponents of the dose, gamma and neutron dose, separately
(Little and Muirhead 2000;Pierce and Preston 2000). This allows for a better assessment
of the contribution the neutron component of dose makes on the dose response curve, and
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allows for the correction to be combined with a different relative biological effectiveness

(RBE) values in calculating the weighted dose.
The issue of a systematic underestimation of the neutron dose also has an impact
on the shape of the resulting dose response curve.

The issue arises when looking at

experimental neutron activation measurements; these indicate that there are large
discrepancies between the
measurements in Hiroshima.

DS86

neutron estimates

and the neutron

activation

The initial discrepancies were noticed in thermal (slow)

neutron activation measurements (Straume et al. 1992) and tentative corrections were

made to bring the DS86 dose estimates in line with the thermal neutron measurements.
Kellerer et al. (1997) investigated the effects of adjusting the dose estimates and found
that although a linear model fit the data a purely quadratic function of gamma exposure
was also consistent with the data. Recent improvements in accelerator mass spectrometry
have allowed for the measurement of 63 N i in copper samples to detennine the fast neutron
fluences, which is more representative of the exposure doses (Ruhm et al. 2000).
Therefore, to realistically estimate the neutron contribution, corrections should be made
to bring the DS 86 neutron estimates in line with the fast neutron activation measurements
instead of the slow neutron activation measurements (Kellerer and Walsh 2001;N ational

Research Council 2001).
The neutron relative biological effectiveness is the estimate of how much more
efficient high-LET radiations are at causing at set biological effect compared to photons
per unit of absorbed dose (Britten et al. 2001). Therefore, weighting factors, that depend
on the neutron energy, have been adopted to best represent the RBE of low doses with
regard to stochastic late effects (Kellerer and Nekolla 1997). In radiobiology the unit
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gray (Gy) is used to represent joules per kilogram (J/kg), the individual dose
measurements, and sieverts (Sv) are the unit used to represent the dose equivalent, when
the difference in effectiveness (RBE) is accounted for. In the assessments of cancer risks
due to radiation exposure calculated based on the atomic bomb survivor data the average
dose equivalents are calculated for each stratum using a constant RBE of 10 (Pierce et a1.
1996b). Radiation biology studies have shown that RBE is not a constant value; instead
it varies with radiation dose, so that the larger the dose the smaller the RBE (Straume et
al. 1992). The large effects of small errors in the low dose region make it important to
consider all known components that effect dose estimates including a variable REE when
modeling cancer risks.
The dose-response relationship between exposure to ionizing radiation and cancer
risks in humans has primarily been analyzed using Poisson regression techniques,
although the use of biologically based models has gained attention in recent years (Kai et

a1. 1997).

The model is not focused on the low dose behavior, but has provided

perspective on the temporal behavior of risk after acute exposures to ionizing radiation
(Little 1999). The atomic bomb data is a high dose high dose rate data set in which
subj ects were exposed to acute doses of mixed radiation; therefore, the infonnation
available is not sufficient to provide insight into the cancer effects of
•

exposure pattern - radiation quality, low doses, low dose rates, protracted or
fractionated exposures

•

risk modifiers - including genetic differences as well as other factors

•

dose weighting factors - relative biological effectiveness, dose rate effectiveness
factor
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(Cardis et al. 2001).
Knowledge gained from experimental animal studies is used supplement the
infonnation that is provided by the epidemiological data used in estimating the risks of
radiation exposure on human populations.

Evidence indicates that the magnitude of

cancer effects varies with radiation quality, dose, dose rate, cancer endpoint, and other
factors; that cannot be directly estimated from the human studies.

Therefore, dose

weighting factors have been calculated from in vivo and in vitro cell line studies and
animal studies and are applied in risk assessment.

2. SPECIFIC AIMS
The goal of this research is to investigate the low dose region of the cancer dose
response curve for exposure to ionizing radiation. The specific aims of this research are

to:
1.) To compare the fits of the threshold models before and after the incorporation
of the appropriate dose adjustments are made for the uncertainty in the dose
estimated and systematic error in the neutron component of dose.
2.) To explore the effects of a dose dependent RBE on the shape of the dose

response curve at low doses.
3.) Investigate the similarities and differences in the dose response curve and risk
estimates between the empirical survivor models and biologically based
survivor models.
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4.) Examine the effect of exposure pattern (dose fractionation and radiation
quality) on the shape of the dose-response curves for total cancer, solid
tumors, and leukemias using animal data.

3. REVIEW OF LITERATURE
3.1 Dose Uncertainty Adjustment
The data available from RERF does not contain the true gamma and neutron

doses (D)' and Dn respectively), because these values are unknown; the doses available in
the LSS data are nominal doses (dy and d n
reconstruction.

-

dose estimates) based on an elaborate dose

Inherent in a dose reconstruction is a non-negligible amount of dose

uncertainty, due to random and non-random errors in the reconstruction process (Kaul
1989). Random error in the dose estimates have been shown to alter the shape of the
dose response curve (Little and Muirhead 1996;Pierce et al. 1990), and result in the
incorporation of a systematic bias in the risk estimates (Little and Muirhead 2000;Pierce
et al. 1992), therefore nullifying any available evidence for linearity or curvilinearity
(Stram 1989).
The issue of dose uncertainty in the RERF dose estimates has been investigated,
and it has been determined that the probable form and magnitude of the error follow a
log-normal distribution with the coefficient of variation somewhere between 25 and 45%
(Gilbert 1984;lablon S. 1971), although in the majority of studies that account for the
uncertainty in the dose estimates it is assumed to be 35%. Methods developed in Pierce
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et al. (1990, 1992) use the infonnation on the distribution of the of the uncertainty in the
doses (log-nonnal), the assumed distribution of the true doses (Weibull) and the
empirical distribution of the nominal doses in adjusting the total dose estimates (dy +
10dn). The average true dose given the nominal dose (Avg[D I d]) is calculated for every
cell in the data (Pierce et aL 1990, 1992) using

Av [D I d] =

L f(D,d)· D· tiD

Lf(D,d). ~D '

g
where

e8
1

f(D,d) ==

2

D

(02-1)

exp

{_

e DB2 }. exp{[IOg(D )-log(d )]2 }
j

1

20-

2

~

d j er v 21t

These adjusted doses have been included in the most recent mortality data made available
by RERF. When Avg[D I d] is used in place of the nominal dose so that the model so we

are modeling A vg[A(D) I d] instead of A(D), but the estimated regression parameters
(Little 2000). The problem with these corrections is that they require that the RBE be
fixed at 10 and don't allow for a correction of the neutron doses. The methods developed
by Pierce et al. can been generalized so that they are applied separately to the neutron and

gamma components of the dose (Little and Muirhead 2000;Pierce and Preston 2000).

3.2 Systematic Error in the Neutron Dose Estimates
The DS86 was published in 1986 as the replacement for the previous dosimetry
(T65D). The major change in the new dosimetry were in the neutron dose estimates in
Hiroshima - the neutron doses were reduced from approximately 20% of the total dose to
about 2% of the total dose while the gamma dose increased by a factor of 2 to 3.5
depending on the distance from the hypocenter (Roberts 1987). The doses in Nagasaki
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were also altered, although the changes were much smaller; the gamma dose was slightly
reduced and the already minimal neutron doses further reduced.
Even with these corrections in the neutron doses there still appear to be
discrepancies with the more recent neutron activation measurements (Kellerer and Walsh

2001). The new measurements indicate that the neutron component of dose has been
systematically underestimated for distances beyond 1 to 1.5 kilometers (Straume et al.

1992). Therefore, Straume suggests that in order to obtain more realistic estimates of the
neutron contribution the neutron doses must be corrected upwards in line with the
neutron activation measurements as a function of the distance from the hypocenter using
the relationship
K'

=

C(r)-K

where K' is the corrected free in air kenna (measurement of radiation in the air), K in the
uncorrected (DS86) free in air kerma, and C(r) is a correction factor that is a function of
ground distance in kilometers from the hypocenter (Kellerer and N ekolla 1997). Since
there is a direct relationship between free in air kenna and absorbed dose the relationship
for between corrected and uncorrected dose is the same as for free in air kerma.
Although the latest data on fast neutrons has not been published the relationship between
the gamma and neutrons doses has been discussed (Kellerer and Walsh 2001;National
Research Council 2001) and this relationship is used to calculate a tentative correction for
the neutron activation measurements.
Calculating the correction factor as a function of distance introduces a problem
because there is no infonnation on distance from the hypocenter available in the data.
Keller and Nekolla (1997) suggest that C(r) can be inferred from the magnitude of the
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gamma component of dose, since dose and distance are related and the gamma dose is the
most highly correlated dose since it is the least dependent on shielding factors.

3.3 Dose Dependent RBE
In previous analyses and reports on cancer risks based on the atomic bomb
survivors it has been acknowledged that neutrons are more effective at producing the a
biological effect than gamma radiation (Committee on the Biological Effects of Ionizing
Radiation 1990;ICRP 1991;ICRU 1986;United Nations Scientific Committee on the
Effects of Atomic Radiation 1994).
defined as RBE n (D n ) =

D
-Y ,

In general the RBE for a given neutron dose is

where Dy is the gamma dose required to produce the same

Dn

biological effect as a given dose neutron dose (Dn) (Britten et al. 2001). Most of the
current infonnation on the neutron RBE comes from experimental animal data, not
epidemiological data (Kellerer and Walsh 2001 ;Little 1997).

Although it has been

accepted in principle, that as dose decreases RBE must increase (Abrahamson 1989), it
has not been incorporated in the analysis of the atomic bomb data until recently because
the it cannot be calculated directly from the RERF data (Kellerer and Nekolla 1997).
Therefore, in the cancer incidence and mortality reports on the atomic bomb survivors a
fixed weighting factor of lOis used in place of a dose-dependent RBE (Mabuchi et al.
1994;Preston et al. 1994;Ron et al. 1994;Thompson et al. 1994).
Radiation biology studies of chromosomal aberration In human lymphocytes
(Edwards et al.

1980) suggests that the dose-independent RBE results in an

overestimation of the risk associated with the neutron component of dose (Rossi and
Zaider 1990;Stram et aL 1993). Rossi and Zaider (1996) have shown that using the data
obtained from human lymphocyte chromosomal aberration studies a reasonable dose-
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dependent RBEn can be calculated using the linear-quadratic model for the effects of
gamma rays (aydy + J3ydy2) and a simple linear model for the neutrons (Undn ) (Rossi and
Zaider 1996). In the event of a mixed exposure the RBEn is dependent on both the
neutron and gamma doses so that the REE is calculated as

where ay= 1.57xl0-2 Gy-l, ~y= 5.0x10-2 Gy-2, and <Xn = 83.5xl0- 2 Gy-l (Edwards et al.
1980).
The Poisson regression models given in the RERF reports are easily adjusted to
allow for a variable RBE with an adjustment for the dose uncertainty and the neutron
correction factor corrected dose so that the total dose would be d = d y + RBE( dy,dn)'dn,
where the d is the Avg[(D y + RBE(Dy,Dn)'Dn )

I dy,

dnJ and d n is corrected in line with the

neutron activation measurements. Using these methods the RBE in the data ranges from
2.3 at approximately 500 meter from the hypocenter to values as high as 53 at further

distances from the hypocenter (Pierce et a1. 1996a;Rossi and Zaider 1996).

3.4 Two-Stage Clonal Expansion Model
The goal of biologically based dose-response modeling is to used information
obtained from basic science to inform a quantitative models of a disease process
(Moolgavkar et al. 1988). Most biologically based carcinogenesis models are stochastic
population models that describe the carcinogenesis process as the temporal evolution and
growth of cells in several distinct stages. The two-stage clonal expansion model is the
mathematical

idealization

of

the

initiation-promotion-progression

theory

of

carcinogenesis (Moolgavkar 1986).
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In order to apply the two-stage clonal expansion model many assumption must be
made about the cells, their behavior in the different stages and the endpoint of interest. It

is assumed that at any given time in the study period there is a large, constant number of
somatic cells (Xo) that are susceptible to genetic transfonnation, the initiated cells «Xl(t»
reproduce in a stochastic manner, and that once a malignant cell (X2 (t» is formed it will
inevitably become an observable tumor (Kopp-Schneider et al. 1994;Nakamura and Hoel
2002;Shennan and Portier 1997).

Normal
Cells [Xo]

(

Initiated
CeUs [Xl(t)]

~

Initiation

Malignant
Cells [X2(t)]

__..."A. . . __. . .
( Promotion '\

Progression

Figure 1 - The two-stage clonal expansion model where J..lI is the mutation rate of normal cells (per unit
time); J.l2 is the mutation rate of initiated cells (per unit time per cell); J3is the birth or replication rate of
initiated cells (per unit time per cell); and 0 is the death or differentiation rate (per unit time per cell).

The model consists of four time-independent parameters J.l), J.12, (3, 5 seen in
Figure 1. Each nonnal cell has a non-zero probability of undergoing a transformation
into an initiated cell at a constant mutation rate of J.ll per unit time. Where the mutation
rate is calculated as the product of the transition rate per unit time per cell and the number
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of nonnal cells, so that Jl1 =v Xo.

Any agent that enhances the probability of such an

event is referred to as an initiator. Through replication, initiated cells can develop into
clones of initiated cells at a rate of ~ per unit time per cell, differentiate or die at a rate of

B per unit time per cell, or they can be transform into a malignant cell at a transition rate
of Jl2 per unit time per cell (Kopp-Schneider et al. 1994). Any agent that results in an
increase in the difference between the replication rate (13) and the differentiation rate (8),
the net proliferation rate, is referred to as a promoter (Heidenreich et al. 1997). Once a
malignant cell develops, it loses growth control and in a relatively short period of time
will become a tumor; therefore, the fonnation of a single malignant cell is identified with
the development of cancer (Heidenreich et al. 1997 ;Moolgavkar 1986).
The model's parameters (8) are always positive so a log-linear transfonnation is
applied to each parameter,

where the total accumulated gamma or neutron dose is represented as D, a is a constant
term, and bo and b I are regression coefficients. Due to the lack of identifiability that has
been shown when estimating the four parameters from tumor incidence data (Hanin and
Yakovlev 1996;Heidenreich et al. 1997), the parameter space must be reduced. This can
be accomplished by fixing a parameter to a set rate, setting the transition rates equal to
another (v = J.!2) or the replication rate equal to the differentiation rate (~
reparameterizing the parameter space.

= 0), or

It has been shown that the parameter estimates a

MLE estimate can be generated using a combination of reparameterization and setting the
differentiation rate equal to zero (8=0) so that
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where the "*,, is used to denotes the parameters that are conditioned on ()=o. Maximum
likelihood estimates (MLE) of the parameters are obtained using the reparameterized
conditional likelihood equation as described in the appendix of Paper II and Paper Ill.
More details on this method and a detailed comparison of the conditional and original
likelihood are discussed in Nakamura and Hoel (unpublished paper).

4. DATA SETS

4.1 RERF Atomic Bomb Survivorship Data
The extended Life Span Study (LSS) is the follow-up of the cohort of atomic
bomb survivors in Hiroshima and Nagasaki. The doses included in this data set are the
most recent estimates using the Dosimetry System 1986 (DS86).

This study can be

broken into parts; in this study we are interested in both the incidence and mortality data
sets for solid tumors and leukemia.
The solid tumor incidence data consists of all survivors that were alive as of
January 1, 1958 and follows them through December 31, 1987. This data contains 79,
972 people with a total of 1,950,567 person years at risk after survivors were excluded
because they were not in either of the cities at the time of the bombings, their vital
statistics were not available, they had DS86 doses greater than 4 Gy, or they had cancer
prior to January 1, 1958 (Thompson et al. 1994).

Tumor cases were determined by
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matching this data with the Hiroshima and Nagasaki Tumor Registry where 8613 cases of
solid cancer were reported (Hoel and Li 1998).

For the leukemia incidence data the cohort includes all survivors that were alive
as of October 1, 1950 and follows them through December 31, 1987, including 86,293
persons contributing 2,554,000 person years at risk, after elimination of survivors in
which vital statistics were unattainable (n=45), DS86 doses were unavailable (n=71 03),
DS86 doses were greater than 4 Gy (n=262), and people with cancer prior to October 1,
1950 (n=38) (Preston et al. 1994). This cohort is matched with the Leukemia Registry
where there are a total of 339 reported cases of leukemia (Hoe! and Li 1998).
The most recent follow up for the cancer mortality includes data from 1950
through 1990, which includes an additional 10,500 more survivors with recently
estimated doses (approximately 550,000 person-years) bringing the number of survivors
to 86,572. There are 7827 cancer deaths of which 7578 are solid tumors and 249 are
leukemia (Pierce et al. 1996b).

4.2 JANUS Mouse Data
The majority of the Argonne National Laboratory (ANL) studies, including the
JANUS program, were designed to study the biological consequences of occupational

levels of exposure to radiation on young adult animals (onset of exposure was at
approximately 100 days of age). Between 1971 and 1992 the JANUS program at the
Biological and Medical Research Division of Argonne National Laboratory compiled a
database on the responses of both male and female Fl hybrid B6CFl mice (a cross
between C57BL/6Jani ad BALB/cJAnl mice) to external whole body irradiation (Carnes
and Grahn 1991). The mice were either exposed to fission neutrons (mean energy 0.85
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MeV) or 60Co y-rays over a range of total doses delivered as either a single exposure or
protracted exposures.

Three basic patterns of exposure were investigated: (1.) single

exposures, (2.) 24 once-weekly exposures and (3.) 60 once-weekly exposures.

All

irradiations were terminated at predetennined total doses, with the dose calculated at the

midline of the mouse. The mice were then followed for the rest of their natural lives; at
which point pathology and histology reports were used to detennine the cause of death
(Grahn et al. 1992).
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ABSTRACT:
Cancer incidence and mortality data from the cohort of Japanese atomic bomb
survivors has been adjusted for uncertainty that exists in the dose estimates, systematic
error in the neutron dose estimates, and a dose-dependent relative biological
effectiveness. Once the adjustments were incorporated in the dose estimates the data was
analyzed to allow for the possibility of a threshold dose response. The dose response
models that were fit to the data were the same models used in the original papers.
A threshold term was included in the model with possible threshold values ranging from

o to

0.35 Sv. These analyses suggest that for the A-bomb solid tumor and leukemia

incidence data a threshold term significantly improves the fit to the purely linear or linear
quadratic model. The results from the mortality data suggests that the leukemia data
agree more with the threshold model than the linear quadratic model although the linear
quadratic model is statistically equivalent, while the solid tumor data does not suggest
any improvement with a threshold.
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INTRODUCTION:
Radiation protection agencies estimate radiation-induced cancer risks based on
epidemiological studies of the Hiroshima and Nagasaki A-bomb survivors., medically
irradiated patients, and occupational cohorts using the traditional linear no-threshold
model. Debates on the scientific basis of the linear hypothesis have appeared in recent
literature (Goldman 1996;National Council on Radiation Protection and Measurements
2001). The linear no-threshold assumption has been adopted as a "pragmatic guideline in
the absence of scientific certainty" because the complexities of cell responses at low

doses cannot be resolved with epidemiological studies.

Recent observations-such as

genomic instability, bystander effect, and adaptive response are complexities that can
modify the response at low doses, which if inducible in humans may invalidate some of
the arguments that favor the linear no-threshold model (Kellerer and Nekolla 2000).
The Japanese A-bomb survivor Life Span Study (LSS) cohort is the principal
dataset used in assessing the cancer risks following exposure to ionizing radiation (United
Nations Scientific Committee on the Effects of Atomic Radiation 1994). This population
was exposed at high dose rates; therefore, the risk estimates must be extrapolated to
derive estimates of cancer risks for the general public and occupational groups who are
exposed to relatively low-dose protracted exposures.

Models have been developed to

extrapolate between high and low doses from both acute exposure and chronic or
protracted exposures, and across time (Cardis et al. 2001).

The problem is that these

models inevitably introduce uncertainty into the estimates and have been the center' of
debate for many years.
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It is generally accepted that high dose, high dose-rate radiation induced cancer
data are well described by a linear dose-response, the issue of interest in radiation risk
assessment is the shape of the dose-response curve at low-doses. The problem is that
non-linearities are almost impossible to observe or rule out at low-doses in
epidemiological data (National Council on Radiation Protection and Measurements
2001).

This is because the cancer risks at low doses are too small to observe and

confounders exist that cannot be controlled for in human populations. There is also the
issue of uncertainty and error in the dose estimates and their potential impact on the doseresponse curve. Studies have shown that errors in the dose estimates can substantially
alter the shape of the dose-response relationship, thereby nullifying any evidence for
possible non-linearity in the dose-response (Little and Muirhead 2000).

The issue of

uncertainty in the Radiation Effects Research Foundation (RERF) data has been
investigated (1 ablon S. 1971 ;Pierce et a1. 1990;Little and Muirhead 1997,2000).

The

presence of random errors in the dose estimates is from the uncertainty that is involved
with any dose reconstruction and the bias introduced by the uncertainty in the survivors"
location results in an overestimation of dose, and in tum, an underestimation of the
radiation effect in dose-response analyses (Pierce et al. 1990).
Another issue of concern with the current dose estimates used by RERF is that
discrepancies exist between the calculated and the experimental neutron activation
measurements. Experimental activation measurements of thennal (slow) and fast
neutrons from 36Cl and

63 Ni

respectively suggest that a readjustment of the neutron doses

is needed (Kellerer and Nekolla 1997;Kellerer and Walsh 2001;Straume et a1. 1992).
These measurements revealed a systematic underestimation of the neutron component in
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the dose estimates, especially at smaller doses (survivors beyond 1 kIn) (Rossi and Zaider
1996;Little and Muirhead 2000).

Recent advancements in accelerator mass spectrometry

have made it possible to detennine the fast neutron fluences in Hiroshima using
measurements in copper.

Preliminary

63 N i

measurements have discounted the earlier

tentative correction based on slow neutron activation measurements using
unpublished

63 N i

63 N i

36 C l.

The

activation measurement data are unconfirmed, although the relationship

between neutron and gamma doses was discussed by the National Research Council
(National Research Council 2001).
The acute effects of neutron exposure are known from radiobiological studies,
while their capability to produce late effects such as cancer, are not known from human
observation. The most reliable infonnation on the late effects of neutron exposure comes
from experimental animal studies, but due to the uncertainty in these results cannot be
directly extrapolated to man. Since neutrons are the more effective ionizing radiation, a
lower absorbed dose of neutrons than ,,(-rays is needed to produce the same biological
effect, therefore a relative biological effectiveness (RBE) value is used in calculating the
cancer risk estimates of neutrons and y-rays (Edwards 1999).

The dose equivalent,

measured in Sieverts (Sv), is simply the product of the RBE and the absorbed dose and
results in a risk estimate that can be applied equally to the neutrons and ,,(-rays.

The

major analyses of the LSS data have assumed a constant weighting factor of 10 or 20 for
the neutron RBE, even though radiation biology has shown that the neutron RBE
increases with decreasing dose (Rossi and Zaider 1996). The problem is that RBE cannot
be extracted with any certainty directly from epidemiological data (Edwards 1999), an
attempt to calculate RBE using the A-bomb data resulted in and estimated RBE of
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70 (+50) (Zaider 1991).

Rossi and Zaider (1996) and Pierce et a1. (1996) present

methods using parameters extracted from human lymphocyte aberration data to calculate
a dose-dependent RBE that can be applied to the A-bomb data.
Analyses of the unadjusted dose estimates have indicated using linear threshold
models (as a surrogate for non-linearity) that the addition of a threshold tenn significantly
improved the linear-quadratic model dose response model for leukemias (Hoel and Li
1998). It has since been suggested that this finding is an artifact of the uncertainties that
exist in the dose estimates; and if they were accounted for, there would be no evidence
for a threshold in the linear-quadratic model (Little 1999).
The purpose of this paper is to reinvestigate the threshold dose response models
after simultaneously adjusting for the uncertainty in the dose estimates, the systematic
underestimation of the neutron component as a function of distance from the hypocenter,
and a dose-dependent RBE. Specifically we will evaluate the models with the original
uncorrected dose estimates, doses corrected for both the uncertainty and systematic error
in the neutron dose estimates (using the new fast neutron activation measurement) with a
fixed (RBE

=

10) and a dose-dependent RBE.

MATERIAL AND METHODS:
The Study Population

The data being used in these analyses is the publicly available cancer incidence
and mortality data of the RERF's LSS cohort with doses less than 4 Gy. The solid tumor
incidence data includes the 79,972 survivors of the cohort who were alive as of January
1, 1958. The solid tumor cases were determined by matching the survivor data with the
Hiroshima and Nagasaki Tumor Registry-as of December 31, 1987 a total of 8,613
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cases were found (Thompson et al. 1994;Mabuchi et al. 1994). The leukemia incidence
data includes 86,293 survivors who were followed from October 1, 1950 through the end

of December 1987, matched with the Leukemia Registry for a total of339 leukemia cases
(Preston et al. 1994).

The most recent mortality data has an extended follow-up through

1990 and uses death certificate data for cancer mortality-this cohort includes 86,572
survIvors with 7,578 cases of cancer, including 249 cases of leukemia (Pierce et al.
1996b).

Statistical Methods
Poisson regression methods similar to those used in the original studies by Preston
et al. (1994) and Thompson et al. (1994) are used in the following analyses.

This

approach divides the data into cells based on city, gender, age-at-exposure, follow-up
time, and weighted organ doses. Using Poisson regression models for cancer incidence
assumes that the number of cases in each of the cells is a Poisson random variable with
the mean and variance equal to the product of the person years at risk (PYR) and the
incidence rate.

AMFIT (Preston et al. 1991) is used to fit the model to the data,

calculating the deviance, as a measure of the goodness of fit. The deviance is distributed

approximately X2 with degrees of freedom equal to the difference in the number of cells
and the number of parameters included in the model.

The addition of a threshold tenn

significantly improves the models if the deviance is reduced by a value greater than the
critical value ofaX2 distribution with 1 degree of freedom (3.84 for a=O.05).
The general class of models for the solid tumor incidence, A(D), and the subtypes
of solid tumors are of the fonn

A(D ) = A. (c , S , a, y ).

[I + ERR (D, e, s, a )] ,
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where ACe, s, a, y) is the background incidence rate that depends on city (c), sex (s),
attained age (a), and year (y).

The other term in the model is the excess relative risk

(ERR) which is modeled as a function of the true total dose (D), where the total dose is
made up of the dose of y-rays (Dr) combined with the product of an RBE value and the
neutron dose (Dn), age-at exposure (e), sex (s), and attained age (a).
The leukemia incidence models are similar but are modeled using excess absolute
risk (EAR) :

A(D) = A.(c, s, a,y) + EAR(D, e, s, t),
where

t

is the time since exposure. The models used in these analyses are those used in

the original studies for solid tumor incidence by Thompson et a1. (1994), leukemia
incidence by Preston et a1. (1994), and mortality by Pierce et a1. (1996).
Dose thresholds are added to a model OfA(D) by defining the cancer rate as
A(Dld o )=

A(n ~ do)

="-.(0)

for all
for all

where do is the given threshold dose (Hoel and Li 1998).
The gamma and neutron doses (dr and d n ) available in the data are estimated doses
because the true doses (Dr and Dn) are not known. It has been shown that by replacing
A(D) with the average [A.(Dld)] in fitting the model,

avg lA(D y' D n ~ d y' d n

)J = A(C, s, a, y ). b+ ERR (D

y'

D n , e, s, a)J,

the parameter estimates are still approximately unbiased. This method is comparable to
the methods used by Pierce et al. (1990) and Little and Muirhead (1996, 1997, 2000). In
this analysis, the errors in the neutron and gamma dose estimates are accounted for
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separately, similar to Little and Muirhead (2000), where the parametric form of the true
dose is the probability of a true dose exceeding any value D and is given by the Weibull
distribution exp(- 9 1D 8 2

).

The parameters 8 1 and 9 2 are found for each combination

radiation type, so that the resulting distribution matches that of the estimated doses
(Pierce et al. 1990;Pierce et aL 1991). The distribution of the estimated dose given the
true dose, f( diD), is assumed to be log-nonnal with median D and coefficient of variation

d which is approximately equal to the standard deviation of log(d). A log-normal model
J

with a geometric standard deviation (GSD) of 30% to 40% was suggested based on the
nature of the major sources of uncertainty in the dose estimates (Jablon S. 1971). The
results in this paper are based on the log-nonnal 35% error model.
Since the DS86 neutron dose estimates may be systematically underestimated, a
tentative correction was used to bring the neutron doses in line with the measurements of
activation by the slow neutrons.

The work from Straume et al. (1992) and Kellerer and

Nekolla (1997) suggests the following relationship:
d~

where

d~

== C(r)d n

is the corrected mean neutron dose and C(r) is the correction factor which is a

function of the distance (r) from the hypocenter of the bomb, measured in kilometers.
Since the RERF data set does not contain data on distances from the hypocenter, they
must be inferred from the relationship between dose and distance as given in Table 40 of
Kerr et al. (1987) and the mean shielding factors given in Pierce et al (1996a).

The

relationship between gamma dose and distance is less dependent on the shielding than the
neutron dose (Kellerer and Nekolla 1997), and therefore used as the surrogate for
distance in the correction factor C(r).

We used very similar methods in calculating a
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correction factor to bring the neutron doses in line with the fast neutron measurements.
This correction is shown as the ratio of the neutron to gamma dose in Figure 1.
The importance of a dose-dependent RBE in analyzing the A-bomb data is
another issue that has been debated.

Although most studies have applied dose-

independent RBE's, radiation biology suggests the need for a dose-dependent RBE
(Rossi and Zaider 1996), which can be calculated frqm human lymphocyte chromosomal
aberration data (Edwards et al. 1980). Since the exposures in Hiroshima and Nagasaki
were a combination of y-rays and neutrons, both doses must be used in calculating the
neutron RBE. Using the assumptions of Rossi and Zaider (1996) and the equation for an
RBE of mixed exposure from Pierce et al. (1996),

RBE(D

Y'

D) =
n

J

. [- ( 1 + -2f3., . D Y +
2A
D
Py
n
u
u.,

y

(

2~y
a

l+--·D
Y

Y

J2 + 4J3.,<X
a

2
y

n

·D

n

1

we can calculate an approximate dose-dependent RBE for each dose. In the RERF data
sets, small neutron doses (less than 0.001 Gy) are set equal to zero. This problem does
not affects risk estimates when the typical RBE values of 10 and 20 are used in
calculating dose; however, it has been shown that when the RBE is dependent on dose the
smaller doses result in larger RBEs and the problem becomes appreciable. To fill in the
missing values of neutrons, a combination of the mortality and incidence data was used to
determine the average overall relationship between the neutron dose (d n ) and gamma dose
(dy), before and after the fast

(63 N i)

and slow

(36 C I)

neutron activation measurement

corrections were made to the neutron dose estimates, shown in Figure 2.

This

relationship was then used to replace the percentage of the mIssIng values that
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corresponds to survivors whose doses were set equal to zero (the cohort also included an
essentially unexposed group sample beyond 3 km) (Pierce and Preston 2000).

RESULTS:
Solid Cancer
In Table 1, the RBE values are calculated for the corrected (adjusted for dose
uncertainty and error in the neutron doses) and uncorrected doses and given as an average
for each dose group. A ratio of the average dose, with a variable RBE to those with a
constant RBE of 10, are given to illustrate the effect of the variable RBE on the total
weighted dose, where the weighted dose is calculated as dy + RBE(dy,dn}dn

.

The effect

of a variable RBE is an increase in the estimated doses for doses originally less than one
Sv and a decrease in the dose estimates for those greater than 1 Sv. This finding is more
dramatic for the low dose groups once the adjustments for uncertainty and error have
been incorporated.
Table 1 - Estimated average RBE values and ratio of the variable RBE dose to the fixed RBE (=10) dose
for weighted dose groups using the corrected and uncorrected doses

Weighted Dose 1Svl

RBE
Uncorrected

Dose RBE(Var)
Dose RBE(lO)

RBE
Corrected

Dose RBE(Var}
Dose RBE(lO)

< 0.10

0.10-0.25

0.25-0.50

0.50-1.0

1.0-1.5

1.5-2.0

> 2.0

46.0

27.6

17.4

10.0

6.1

4.6

3.5

1.07

1.07

1.03

1.00

0.97

0.95

0.94

45.2

26.5

16.9

10.1

6.3

4.7

3.7

1.46

1.25

1.12

1.03

0.96

0.94

0.91

In the original analysis of solid cancer incidence by Thompson et al. (1994), the
data were adjusted for city, sex, age-at-exposure, and calendar time, with the excess
relative risk assumed to be linear in dose and modified by sex and age-at-exposure. The
background risk of cancer is modeled parametrically with a log linear function of city,

- 34-

6.1

Corrections in the Atomic Bomb Data to Examine Low Dose Risk

sex, year of birth, log age, and log age squared. Hoel and Li (1998) observed that the
fitted dose response curve underestimates the number of cancers in the zero dose group

while overestimating the lowest exposure group (0.01 to 0.1 Sv), as one would expect in

the case of low dose non-linearities. These calculations suggest the possibility of nonlinearities in the low dose region of the dose response curve; therefore, a dose response

curve that incorporates a linear threshold term was fit to the solid incidence data. In
Figure 3, the change in deviance score from the linear no threshold model versus the
model's threshold dose are plotted.

Three types of dose values are considered: the

uncorrected original dose, doses corrected for uncertainty and error with a fixed RBE
value, and corrected doses with a dose dependent RBE.

We observe that with

uncorrected doses and fixed corrected doses, a threshold up to 0.1 Sv appears to improve
in the models fit, although there is no significant difference between the linear and
threshold models.

In the case of the variable corrected dose, the threshold provides a

significant improvement in the fit of the model at doses between 0.07 Sv and 0.17 Sv.
Models of solid tumor mortality give a different picture. In the paper by Pierce et
al. (1996), cancer mortality is modeled using a stratified background and an excess
relative risk that is linear in dose and dependent on sex and age-at-exposure. We see that
the addition of a threshold tenn offers no improvement in the fit of the model, but
threshold doses up to 0.15 Sv are not statistically worse from the no threshold model,
shown in Figure 4, where the change in deviance is plotted for the three different dose
estimates as a function of the threshold dose.
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Leukemia
Data on leukemia incidence from Preston et al. (1994) was used to examine the
dose response curve for total leukemias.

At doses less than 0.30 Sv the linear no

threshold model based on the doses available in the RERF data, overestimate the risk of
leukemia predicted from the corrected doses and threshold models. A threshold term was
incorporated into the models as was done with solid tumors. Figure 5 shows the change
in the fitted deviance values plotted versus the threshold doses used in the model. In the
cases of leukemias, we see an improvement in the fit of the model with the addition of a
threshold. The threshold model provides a statistically better description of the data than
is seen with the no threshold model for threshold values up to 0.15 Sv with the
uncorrected doses and fixed corrected doses and up to 0.2 Sv for the variable corrected
doses. The results of adding a threshold for the subtypes leukemia were similar to the
results for the uncorrected doses presented in Hoel and Li (1998). ALL and CML were fit
with a dose response function linear in dose while AML as was total leukemia were fit
with a linear-quadratic function. For CML the threshold model provided a significantly
better description of the data than the no-threshold model, while the addition of a
threshold for ALL and AML indicated an improvement in fit that was not statistically
better than the no-threshold model.

The original, uncorrected doses, as well as, the

corrected doses have been fit with a linear-quadratic dose function as shown in Figure 6.
We see that the effect of the dose corrections indicate a noticeable difference in the risk
estimates even in the low dose region of the curve.
The leukemia mortality data comes from the same paper as the solid tumor
mortality by Pierce et al. (1996), but the leukemia models are more complicated.
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Leukemia mortality is modeled uSIng a parametrically modeled background and an
excess additive risk component that is linear-quadratic in dose and modified by sex, ageat-exposure, and time since exposure. The change in the fitted deviance values is plotted
against the threshold doses for leukemia mortality in Figure 7.

Although we see an

improvement in the fit of the model with a threshold, similar to the leukemia incidence
models, the improvement is not significant with the leukemia mortality data.

DISCUSSION:
Theses analyses have shown that the A-bomb survivor data for radiation-induced
cancers (solid tumors and leukemias) are consistent with a non-linear dose response
model. These findings have been seen with the current dosimetry, as well as with the
doses that incorporate information about the uncertainty in the dose estimates, a
correction for the systematic error in the neutron estimates, and the incorporation of a
RBE value that corresponds with current radiobiological knowledge.

The estimated

threshold levels depend on the dose estimates that are used. For solid tumor incidence,
the incorporation of the uncertainty and error corrections indicate a more pronounced
improvement in the fit. Furthennore, when the variable RBE was added, the threshold
model became significantly better with an optimal threshold value between 0.10 and 0.15
Sv-in the case of leukemia incidence, the results were the opposite. The uncorrected

dose resulted in the most significant improvement with a threshold of about 0.1 Sv, the
fixed corrected doses was less significant but with approximately the same threshold, and
the variable corrected doses resulted the least significant improvement but with a
threshold of about 0.17 Sv. The results from Little and Muirhead (2000) which used a
fixed REE of 20 while correcting for uncertainty in the dose estimates and bringing the
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neutron estimates in line with the slow neutron activation measurements indicated similar
findings to the results in this paper when the RBE is fixed. The solid tumors incidence
data suggests an appreciable upward curvature, although not statistically significant,
while the leukemia incidence data indicated a reduction in the significance of the

curvature. In these analyses with a fixed RBE, the threshold becomes more significant
for solid tumor incidence, although it does not reach statistical significance; while the
threshold model for the leukemia data remains statistically significant, the significance of
the threshold is reduced.
Multiple imputation (Rubin 1987)

1S

a popular statistical method used with

missing data or data measured with error, we applied multiple imputation methods to
impute the true dose given the nominal dose for the solid tumor incidence data.

A

lognonnal model was used to impute the true dose given the nominal dose, and 50
multiple imputation datasets were performed.

The multiple imputation estimates and

standard error estimates were very similar to those obtained using the corrected doses. In
-

particular, using multiple imputation, Pdose = 1.198 (estimated standard error 0.3721);
using the corrected doses, Pdose== 1.186 (estimated standard error 0.3676). Thus, the
similarity of the estimates from these two methods suggests that using the corrected doses
will produce unbiased estimates.
The cancer mortality data did not indicate an improvement with the addition of a
threshold and appears to be inconsistent with the observation of non-linearity in the low
dose region of the dose response curve, even with adjustments for the suggested errors in
the doses. This could be due to a bias introduced due to urban-rural differences. Pierce
and Preston (2000) observed that the distal group (more than 3000 meters from the
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hypocenter) has about a 5% higher cancer mortality rate than estimated for the zero dose
group from the proximal survivors. Although the bias is small, it can substantially affect
the assessment of risk at low doses.
Other studies have been used to assess the effects of low dose radiation in the
production of cancers. A study of cancer mortality in a cohort of Canadian Fluoroscopy
patients, fractionated exposures to low LET radiation resulted in a decreased lung cancer
mortality than would be expected at the same dose from the A-bomb data (Howe 1995),
while the risk of breast cancer mortality was not effected by fractionation (Howe and
McLaughlin 1996).

Experimental animal studies have also provided information

regarding the effect of dose rate on the induction of cancers and have resulted in the
recommendation of a dose rate effectiveness factor (DREF) between 2 and 10 for low
doses of low LET radiation (Committee on the Biological Effects of Ionizing Radiation
1990). If the effectiveness of radiation is reduced when the exposures are protracted, the
result could be an effect of non-linearity at low doses.
Occupational studies of radiation workers have also provided infonnation on the
issue of linearity at low doses. However, when total doses are low, occupational data do
not provide clear evidence of risk because the precision of these studies is limited by the
data and with small exposures, there is the possibility of masking the radiation effect with
the "healthy worker effect" that is often associated with occupational studies (Cardis et
al. 2001). The curvelinear dose response relationship found for leukemia in the A-bomb
data indicates no noticeable risk at doses below 0.20 Sv. Most occupational studies with
low cumulative doses have also shown no excess risk of leukemia at low doses, although
there are some exceptions (National Council on Radiation Protection and Measurements
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2001\. although studies have shown that excess risks of leukemia in occupational studies
are usually associated with dose greater than 0.4 Sv. The problem with these studies, as
with most epidemiological studies of radiation exposure is that they suffer limitations,
which impact the interpretation of the data and may make the capability of resolving the
issue of low dose risk beyond the capability of epidemiological data alone.
The scientific basis for the no threshold model comes from scientific studies of
mutagenesis, clastogenic, and chromosomal aberrations.

Mutation frequencies have

been shown to increase with either linear or linear-quadratic dose response curves,
depending on the radiation quality, LET of the radiation, dose rate, and genetic
background of the cell.

In either case, there is no direct evidence of a threshold;

therefore, if cancer fonnation is directly related to mutation induction the data does not
support a threshold in the cancer dose response, but cannot rule out, a nonlinear dose
response. Chromosomal studies can only lead to predictions of a threshold if DNA repair
is error free at low doses, but the existing data cannot support or refute these predictions.
Although a linear no threshold model fits cellular data for many biological alterations that
may be precursors for cancer, as well as the epidemiological data, it is important to note
that they do not provide evidence that low dose non-linearities or threshold are absent in
the data. Further, the discovery of issues such as genomic and chromosomal instability,
bystander effects, and adaptive response are currently changing the understanding of
radiobiology, and must now be examined to see what effects they have at low doses.

CONCLUSION:
The maIn conclusion that can be made from these analyses is that even after
adjustments are made for uncertainty associated with the dose estimates, systematic error
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in the neutron estimates and a dose-dependent RBE a threshold like dose response is still
consistent with the A-bomb cancer and leukemia incidence data, reinforcing the findings
of Hoel and Li (1998) who found similar results using the uncorrected original doses.
And although a linear no threshold model fits the data it does not provide evidence
against low-dose non-linearities or threshold models.

The shape of the dose response

low-dose is an important issue in radiation protection that cannot be resolved with
statistics and epidemiology; it will require a better understanding of the radiation biology
at low doses and the effects on radiation carcinogenesis.
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ABSTRACT:

A low dose subset of experimental mortality data from experiments conducted at
the Argonne National Laboratory on the effects of exposure of B6CF) mice to wholebody irradiation, gamma rays

«

300cGy) or fission neutrons

«

30cGy), were analyzed

to assess the shape of the dose response and the effects of fractionation.

The Cox

proportional hazards model was used as an empirical model, while the two-stage clonal
expansion model was used as the biologically based cancer model in which information
on the carcinogenesis process is incorporated into the model. The two models resulted in
similar descriptions of the dose response curves, cancer risks, neutron relative biological
effectiveness and dose rate effectiveness factor associated with exposure to ionizing
radiation.

Both models suggest that a dose-response curve linear in dose provides an

adequate fit to the data.

Fractionation reduced the effectiveness of gamma radiation

while had no noticeable impact on the effectiveness of neutron exposure.
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INTRODUCTION:
Many late effects from exposure to ionizing radiation, including cancers, have
been described in the literature. The identification and quantification of radiation-induced

health effects is an important and complex issue.

The recommendations for radiation

safety and protection from the International Commission on Radiological Protection
(ICRP) are made based on the risk estimates for late effects from low dose radiation
(ICRP 1991).

A major obstacle in this process is the limited availability of data to

directly measure the health effects of radiation on human populations. The problem is
further hampered because the data on human exposures do not include the energy
spectrum and patterns of exposure that are most relevant. One way to circumvent this
problem is to use experimental data from laboratory animals and extrapolate across
species to man (Carnes et al. 1998).
Another issue to consider is that there are many models available to generate risk
estimates.

Some models are empirical, purely mathematical and driven by the data,

while others are mechanistic; attempt to incorporate biological plausibility within the
mathematics. Both categories of models have a history in radiation biology and different
issues that related to them. The Cox proportional hazards model is an empirical model

that uses time to event as well as covariate data to describe the data, without considering
what is happening biologically.

A parametric for of the covariate effect is assumed,

while the baseline hazard rate is treat nonparametrically allowing inferences to be made
about the covariate effect, but not the baseline hazard. The two-stage clonal expansion

model, also referred to as the Moolgavkar-Venzon-Knudson model (MVK model), is a
biologically based cancer model that accounts for clonal expansion, replication,
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differentiation, and mutation of the cells in the first altered state (initiated cells) as well as
the mutation rates of nonnal cells. Questions as to whether or not non-linearities exists at
low doses in the dose-response add to the issue and debate over which model should be
used when investigating low dose effects (Hoel and Li 1998).
The two-stage clonal expansion model has been applied to data on radiationinduced cancers in humans and rats as well as other environmental cancers. The A-bomb
survivors data indicated an initiation effect, but contained no information on promotion
(Kai et al. 1997). In studies of Colorado uranium miners exposed to radon (Luebeck et al.
1999) and radon exposed rats (Heidemeich et al. 2000) a promotion effect was necessary
to describe the data.
The two-stage clonal expansion model assumes that at any given time there are a
large constant number of somatic cells susceptible to genetic transformation (Xo), since
all of the animals in this data were irradiated as young adults, the number of normal cells

Normal
Cells [Xo]

Initiated
Cells (Xl(t)]

Malignant
Cells [X2(t)]

Figure 1: The two-stage clonal expansion model where J-li is the mutation rate of normal cells (per unit
time); f..l2 is the mutation rate of initiated cells (per unit time per cell); J3 is the birth I replication rate of
initiated cells (per unit time per cell); and 8 is the death I differentiation rate of initiated cells (per unit time
per cell).
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is constant through the observation. Initiated cells, resulting from a somatic mutation
(Xt(t)) reproduce in a stochastic manner, and once a malignant cell (X2 (t)) is formed by a
second mutation, it will inevitably become an observable tumor (Moolgavkar 1986;
Heidenreich et al. 1997b).
The model consists of four time-independent parameters J.lI,

~,

b, and J.l2 described

in Figure 1. Each normal cell has a non-zero probability of undergoing a transformation
into an initiated cell, at a rate of v per unit time per cell, so that J.11 (= vXo) is a constant
transition rate per unit time.

Each initiated cell may undergo three events; they can

replicate into two intermediate cells at a rate

rJ per unit time per cell, die at a rate of 8 per

unit time per cell, or divide into one malignant cell and one initiated cell at a rate of Jl-2
per unit time per cell.
There is a lack of identifiability because not all four of these parameters can be
determined from tumor incidence data (Hanin and Yakovlev 1996), therefore, it is only
possible to calculate three unique estimates for the parameters.

In order to solve the

system of equations, the parameter space must be reduced either by introducing
additional data, reparameterizing the parameter space, or placing a restriction on the
existing parameters. In this paper, the parameter space is reduced by reparameterizing
into three distinct combinations of the original parameters: (I.) 'V = J3 -

(5 -

Jl2 '

(2.)

P = J.11 Jl 2 , and (3.) 11 = Jll and setting the differentiation rate equal to zero (8==0).
~

The two-stage model can be described in terms of initiation, promotion and
progression (or transformation). Increasing the probability of a normal cell undergoing a
transfonnation into an initiated cell is referred to as initiation. Promotion is the increase
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in the number of initiated cells through clonal growth (increasing the difference between
the replication rate «(3) and the differentiation rate (6)).

The transformation from an

intermediate cell to a malignant cell is referred to as progression. Detennining which of
the stage or stages in the model are affected by radiation, will in tum, help describes the
modifying effect of fractionation.
The objective in this paper is to compare the Cox proportional hazards model with
the two-stage clonal expansion model, to see how well they fit the data and what the say
about the cancer dose effect of radiation.

In doing this we look at what each model

estimates for the relative biological effectiveness of neutron, and the dose rate
effectiveness factor associated with low dose rates of radiation and how these relate to
values used in radiation protection.

MATERIAL AND METHODS:
Data
The JANUS program at the Biological and Medical Research Division of
Argonne National Laboratory (ANL) compiled a database between 1970 and 1992 on the
response of Fl hybrid mice; the B6CF 1 (a cross between C57BL/6
external whole body irradiation.

x BALB/c mice), to

Detailed information concerning the individual

experiment designs, the animals care and maintenance and radiation factors have been
published previously (Grahn et al. 1992,1995).
The data include a total of between 20,000 and 40,000 mice, depending on the
level of pathology. The mice were either controls or exposed to

60 CO

y rays or fission

neutrons (mean energy 0.85 MeV) over a range ofpredetennined total doses calculated in
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centigrays (cGy) at the midline of the mouse. The three basic patterns of exposure
investigated were: single exposure, 24 once-weekly exposures, and 60 once-weekly
exposures. The average age at onset of exposure was 110 days, in order to study the
biological consequences of occupational levels of exposure to radiation on young adult
animals. The mice were followed for the duration of their natural lives, at which point

pathology judgments based on macroscopic examinations (autopsy) were used to
determine the cause of death, as well a subset of these animals were selected at random to
undergo a histological examination (microscopic) (Grahn et al. 1992). Comparisons of
the macroscopic and microscopic pathology records for primary tumors causing or
contributing to death are in agreement 980/0 of the time (Grahn et al. 1995). This suggests
that the macroscopic data, with its larger sample size, can be used reliably for the analysis

of these endpoints (Grahn et aL 1992).
For the analyses in this paper, we are only interested in a subset of the JANUS

data (Table 1) to examine lowest available doses of gamma and neutron exposures and
the effects of fractionating the exposure. Therefore, the data has been restricted to mice
receiving total doses less than 300 cGy gamma ray exposures and 30 cGy for neutrons.

This restriction resulted in the exclusion of the 24 once-weekly data because of the lack
of comparable doses in this dose range.

This subset of the data was the basis of the

recent analysis reported by Carnes et al. (2002)
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Table 1: Summary of the Mice - Exposure Patterns, Radiation Doses, Sample Sizes, and Mean Ages at
Death

Number
of Mice

Primary Tumor
Cases
Percent

Exposure

Dose *

Single Exposure
Gamma

0
86
137
198

987
976
947
923

191
189
150
308

149
153
114
262

78
81
76
85

998
980

87

508

90

967
924

558
562
164
76

483

60 Once-Weekly
Gamma

0
100
200
300

139

0
1
2

19

981
988
973
949
932
921

1026
661
411
312
230
183

791
501
314
222
160
148

0
2
8
14
22

997
987
975
924
913

534
520

450
429

85
90
77
76
76
71
70
81
84
83

204
219
225

173
181
193

Single Exposure
Neutrons

60 Once-Weekly
Neutrons

*

5
9

MAD**

68

85
83

86

Dose - total accumulated dose measured in centigrey (cGy)

* * MAD (± SE) - Mean Age at Death given in days

Statistical Methods
On average, the control mice and the mice with lower exposure doses lived longer
than the mice exposed to higher irradiation doses (see Table 1). Therefore, for the
purpose of comparing the different exposure patterns and dose groups, it is necessary to
truncate the populations at a point in time when there are still some mice alive in all of
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the exposure groups. For these analyses, the data is truncated at 3 years (1095 days) from
the date of first exposure, with any tumors occurring after this date treated as censored.
Dose-response analyses were perfonned to examine the shape of the doseresponse function in the low dose region for each exposure pattern.

Primary tumor,

defined as all tumors that detennined to have caused or contributed to the death of the
mouse, is the endpoint of interest in this study. The results were generated using three
different models:
(1.)

The Cox proportional hazard model (Cox 1972);
A(t I D) =

Ao(t)exp[~'D],

[1]

where t, the time variable, is the days at risk, D is a function of the total accumulated
dose treated as a continuous variable, A(t I D) is the hazard function at time t given dose
D for a mouse, Ao(t) is the unspecified baseline hazard function, and exp[I3'D] is the
relative risk.
To determine the form of dose to be used in the final model three forms of dose
were considered.
Linear dose

D

Linear-Quadratic dose

dOse]
D = [ dose 2

Log-Linear dose

o=

=

dose
, and

[2]

log(dose) .

Each fonn of dose was modeled for each exposure pattern to detennine how well they
described the data. The Akaike selection criterion (Akaike 1976) was used to evaluate
the least squares fitting to the models and determine which was the most appropriate
function of dose to use in the model.
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(2.)

The piecewise linear Cox model is used to examine the possibility of non-

linearity in the low dose region of the dose response curve that would be missed by use of
the linear Cox proportional hazards model (Nakamura et al. 1999). This model uses the
basic Cox proportional hazards model described above, with the relative risk defined as a
linear combination of the original covariate (dose), and a function of the intermediate
dose cut points such as the following model for single gamma exposure,
A(t I D) = A.o(t)exp[~oD +

P1D86 + f32D137]

.

[3]

Table 2 lists the possible dose cut points to be investigated in this analysis for each of the
exposure patterns of gamma and neutron. Stepwise Cox regression methods are used to
detennine which dose cut points, if any, are significant and therefore should be included
in the model.

Table 2: Definition of piecewise linear functions.

Single Exposure
Gamma
Neutron
D86 =max{O, D-86}
·D137=max{O,D-137}

01 =max{O, 0-1}
D2=max{O,D-2}

60 Once-Weekly Exposure
Gamma
Neutron
D1 OO=max{O, D-1 ~O}
0200=max{O,D-200}

D5=max{O,D-5}

02 =max{O,0-2}
D8 =max{O, D-8}
D14=max{O,D-14}

D9=max{O,D-9}

(3.)

In the two-stage clonal expansion model, since the parameters (8) take on

only positive values they are modeled in the log-linear form so that
log(9) = a + bD ,

[4]

where D is the total accumulated gamma or neutron dose given to the mouse, a is a
constant term, and b is the regression coefficient. The maximum likelihood estimates
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(MLE) of the parameters are estimated for the conditional likelihood function using a
simple transformation of the chain rule. Next, these values are converted into the original
parameter values.

More details on the method are available in the appendix; and a

detailed comparison of the conditional and the original likelihood is dealt with in
Nakamura and Hoel (unpublished paper).
To graphically examine and compare the result of the cumulative hazard estimates
from the models discussed above, Kaplan-Meier estimates (K-M) of the observed hazard
were also calculated for each exposure pattern and dose group as a reference.

RESULTS:
The results of evaluating the possible forms of dose in the Cox proportional
hazards model are shown in Table 3. The model was evaluated individually for each
exposure pattern; and in all cases, the Akaike information criterion (AIC) was smallest
for the linear form of dose, indicating that the linear model was the best fit or was
indistinguishable from the other forms of the model. This finding is consistent with
previous life shortening studies that found the dose-response curve to be linear for
neutrons less than 10-50 cGy (depending on the dose-rate) and for the entire range of
gamma irradiation (Storer and Fry 1995;Cames et al. 1989;Thomson and Grahn
1988;Thomson et al. 1985).

Subsequent references to the Cox proportional hazards

model will be in reference to the linear fonn of the model.
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Table 3: Akaike Information Criterion Scores for the various forms of dose explored In the Cox
proportional hazards model for each exposure pattern.

Radiation
Quality
Gamma
Neutron

Exposure
Pattern
Single
Fractionated
Single
Fractionated

* The smallest Ale

ft

Linear
7799.714
15036~837

29724.033
18426.803

Ale Score
Linear-Quadratic
7799.824
15038.815
29725.728
18428.603

Log-Linear
7806.817
15038.152
29727.800
18430.238

Score represent the form of the model that best fits the data and is represented

in bold face.

The results for our examination of possible non-linearity using the piecewise
linear model are given in table 4. For three of the four exposure patterns (all except the
fractionated gamma exposure), the selection process for the piece-wise linear model
found a threshold dose to be more significant than the simple linear dose. In these cases,
the estimated deviance for the threshold model and the linear non-threshold model were
used to test whether or not the threshold significantly improved the fit of the model. For
all exposure patterns, the results indicate that the piece-wise linear model did not fit the
data better than the linear model: single exposure of gamma (p=O.18), neutron (p=O.67),
and fractionated neutron exposure (p=O.62).

Table 4 - Comparison of the linear model to that of the piece-wise linear model for each of the exposure
patterns.

Radiation
Quality
Gamma
Neutron

Exposure Pattern
Single
Fractionated
Single
Fractionated

Significant Cut
Points *

0137

p-value

Dose
01

0.18
1.00
0.67

02

0.62

* Significant cut points are from Table 2
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Radiation can affect the initiation rate, promotion rate, progression rate, or a
combination of these three rates. Therefore, there are seven different forms of the model
that must be considered - those in which only a single stage is affected, those in which
two of the stages are affected, and the model in which all three stages are affected by
radiation. To determine which of the parameters were affected, we calculated the log
likelihood for each of the models. For this data, we determined that the best model to
describe all of the exposure patterns is the one in which J..LI is the only parameter directly
affected by dose.

Although, for most exposures the other parameters did not behave

significantly worse, the J..Ll model was consistently the better model.

The slope

coefficient of 109(J..ll) is positive for all exposure patterns (Table 5), indicating an increase
in the mutation rate with increasing dose.

Table 5 - Parameter estimates from the two-stage clonal expansion model

Exposure
Gamma
Gamma
Neutron
Neutron

Single
Fractionated
Single
Fractionated

log(J,11)
a*
-4.8491
-4.6357
-4.5690
-4.7732

* Each parameter is modeled as logeS)
was not included in the model.

=

b
0.001991
0.001557
0.023354
0.023936

10g«(3)
a
-4.8342
-4.7610
-4.8943
-4.7040

IOg(J!2)
b
---

--

--

a

-12.1220
-12.6930
-12.2242
-12.8462

b

--

----

a + bD. (--) value for a parameter indicates that that parameter

Shown in Figure 2 are the estimated log cumulative hazard rates plotted as a
function of time (days at risk), to compare how well the two-stage model (-) and the
Cox proportional hazards model (---) fit with the Kaplan-Meier ( - step) observed hazard
estimates. The two-stage model is a function of time as a continuous variable (see
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appendix); therefore, its result is a smooth line, where the Cox proportional hazards
model uses individual event times in the model, resulting in a step function.

Each figure

illustrates the results for the control mice (dose group = 0) as well as a higher dose group;
the higher dose groups were chosen to be comparable within each radiation type.
For all exposure groups, both models give a similar fit to the observed values
(Kaplan-Meier) after approximately 600 DAR (days since first exposure). Prior to this
time, the number of observed events is small and the resulting Kaplan-Meier estimates
have large confidence intervals.

The difference between the curves for the two dose

groups represents the effect of the increase in dose. In Figure 2B, we see that for the
same dose there is a noticeably reduced effect for the fractionated gamma exposure
compared to the single gamma exposure in Figure 2A.

When comparing the neutron

exposures (Figures 2C and 2D), there is no visible difference in the effectiveness between
the two exposure groups.

The dose-response curves are shown in Figure 3. The Cox proportional hazards
(-) and the two-stage clonal expansion model ( ---) are plotted with the observed KaplanMeier hazards and the 95% confidence intervals for each dose group as a reference. The
two-stage model estimates the absolute risk for each dose group; consequently, the points

of the curve are fixed, while the Cox proportional hazards model results in estimates of
relative risk.

Therefore, to facilitate comparison, without changing the meaning or

estimated risk, the estimated risk of the control group for the Cox model is set equal to
that of the two-stage model.
We see, in Figure 3, that the two models predict very similar results for all
exposure patterns.

Since the dose response curve for all models is linear in the dose

- 68-

6.2 Comparison of Two Models of Risk Estimation: Part I
range of this analysis, the main noticeable difference in the two models is the slope of the
curves. Once again we can see graphically that the fractionated gamma exposure results
in a reduction of the slope of the dose-response curve, indicating a decrease in the
effectiveness, while there is no noticeable change in the slope for the neutron exposure.

Dose Rate and RBE
There are two measures that are used in the literature to describe the effects of
different radiation quality and dose-rates:

relative biological effectiveness (RBE) and

dose rate effectiveness factor (DREF). The RBE, as defined in BEIR V, is the biological
potency of one radiation as compared with another to produce the same biological
endpoint. The DREF is a factor by which the effect caused by a specific dose of radiation
changes at low compared to high dose rates (Committee on the Biological Effects of
Ionizing Radiation 1990).

The DREF used is similar to the dose and dose rate

effectiveness factor (DDREF) used by ICRP (ICRP 1991) and UNSCEAR (United
Nations Scientific Committee on the Effects of Atomic Radiation 1994) when it is
assumed that at low doses the cancer effect is linear in dose.
It is well established in the literature that high-LET radiations have greater
biological effectiveness than low-LET radiations (Balcer-Kubiczek et al. 1994;Brenner
and Hall 1992). The problem is that the evidence suggests that there is no one RBE value
for neutrons, because the RBE value is dependent on the dose, dose-rate, energy,
fractionation, target tissue, and time (Carnes and Grahn 1991). The neutron relative
biological effectiveness is calculated as the ratio of the linear slope coefficients of the
neutron and the reference radiation (ICRU 1986), in this study 60 CO gamma.
[5]
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SE(RBE) ==_1

with

ay
where a ~ and a ~ are the variance estimates of the slope coefficients.

F or single

exposure, the RBE estimates are 12.46 (+ 4.4) and 11.73(+ 4.0) for the Cox proportional
hazards model and the two-stage models respectively, while the estimates for fractionated
exposures are 19.67 (+ 6.2) and 20.69 (+ 5.9). The increase in the RBE for fractionated
exposures is due mostly (about 800/0) to the reduced effectiveness of gamma at the lower
dose-rates.
To compare the effectiveness of different dose rates for equal doses, dose rate
effectiveness factor (DREF) is used as described above. To estimate the DREF, we fit
data obtained at high and low dose rates separately (single and fractionated exposure) and
used the estimated slope coefficients to calculate the DREF as

with

SE(DREF)u =

as
and SE(DREF)L = as
a f -c
a f +c

[6]

where

The DREF for gamma irradiation is 1.51 (L=1.03 and U=2.4S) for the Cox model versus
1.72 for the two-stage model; while for the neutron exposure, the DREFs are 0.94
(L=O.73 and U=I.22) and 0.99 for the Cox model and two-stage model respectively. The
values are not different than unity; and therefore, indicate that the dose rate of the neutron
exposure at lower doses does not change its effectiveness.
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Table 6 presents the relative risk estimates for each exposure pattern and model,
with the estimates calculated for total accumulated doses of 100 cOy gamma exposure
and 10 cGy neutron exposure. The results indicate that the choice of model does not
affect the estimates of risk. Although, they do suggest a reduction in the effectiveness of
the gamma exposure with fractionation while the fractionation of neutron exposures
indicate no change in effectiveness.

Table 6 - Excess Relative Risk estimates for 100 cGy gamma or 10 cGy neutron radiation exposure for the
Cox proportional hazards model and the two-stage model

Radiation

Gamma
Neutron

Exposure
Single
Fractionated
Single
Fractionated

Cox Model
1.20
1.13
1.26
1.28

Two-Stage Model
1.22
1.12
1.26
1.27

DISCUSSION:
We performed our analysis on mice exposed to single or fractionated doses of
fission neutron or

60 CO

gamma rays in an arbitrarily selected low dose region (less than

30 cGy neutron and 300 cGy gamma) of the available data, the same subset mice used in
Carnes et al. (2002) analysis of non-cancer morbidity.

The data for neutron exposure

had doses ranging from 0-22 cGy, without any major gaps in the lower doses of the data,
which can therefore accurately describe the low dose region, but the data for gamma
exposure was much more limited, with the smallest doses being 86 cOy for single
exposure and 100 cGy for fractionated exposure. The piecewise linear model and the
Kaplan-Meier (K-M) estimates indicate that there may be some [onn of non-linearity in
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the low dose region of the acute gamma exposure. However, the confidence interval of
the K-M estimate was large; and without data for doses between 0 and 86 cGy, it is
impossible to discern it from a linear model. This unfortunate gap in the data affects our
ability to definitively address the issue of linearity in the low dose region of the gamma
dose-response curve.
The endpoint of interest in this paper, primary tumors, can be broken down into
two subcomponents - lymphoreticular tumors (all leukemia and lymphomas) and solid
tumors (all cancer except lymphoreticular tumors). At low doses, all the models for these
subcomponents were similar to that for primary tumor for all exposure patterns_ The
linear Cox model and the J-ll two-stage model were the best fits; so the only variation was
in the slope estimates for the exposure patterns except for single neutron exposure, which
indicated no dose dependence for lymphoreticular tumors at low doses.
The RBEs estimated in this analysis are strictly for comparing the two models and
are not reliable estimates, because in order to have doses and dose ranges that were
comparable between the acute and fractionated exposure, we were forced by gaps in the
data to select female mice for the neutron exposure and male mice for the gamma
exposure. We see that since the estimated RBEs are based on the slopes estimate and the
two models resulted in similar slope estimates, the two models give similar results for
RBE (11_73 - 20.69 depending on fractionation)_ It is interesting to note, that although
these estimates are not reliable, they agree well with earlier sex dependent estimates of
the REE for life shortening studies (Thomson and Grahn 1988;Storer and Mitchell 1984).
The neutron RBEs resulting from the different studies have ranged from 2 to 100
depending on the dose, dose-rate, cell or tissue type being examined, and cancer endpoint
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being examined. The majority of the analyses of the atomic bomb data use an RBE value
of either 10 or 20, these being consistent with the quality factor "Q" of 20 recommended
by national and international groups on radiation protection (Committee on the Biological
Effects of Ionizing Radiation 1990;ICRP 1991).
The reduced effectiveness of gamma radiation seen by both models (DREF

=

1.5

and 1.7) has been reported in many studies including previous analyses for the endpoint
of life shortening in the JANUS data.

Although an increase in the effectiveness of

neutron exposure with protracted doses has been reported, it is not seen until higher doses
(greater than 40 cGy); and therefore, was not expected to be seen in this analysis (Carnes
et al. 1989).
In the two-stage model, the results appear linear for all combinations of dosedependent parameters in the low dose range investigated.

When initiation is the only

stage affected by radiation exposure (J.ll parameter), the dose response curve is linear
over all doses with the slope equal to the regression coefficient of the dose term ( b) in
equation 4. The results of the other models appear linear in the dose range examined,
although they are actually non-linear; this non-linearity becomes more evident at higher
doses.
It is interesting to note that at low doses, the estimated risk from the two-stage
model was not affected by which combination of dose-dependent parameters was used.
Therefore, the decision to use the fJ.l model did not have an affect on the resulting risk
estimates. In deciding to use the mutation rate model for all exposure groups, we
investigated the net proliferation model for the 60 once-weekly neutron exposure because
it provided a similar fit to the data, but was much more difficult to interpret in tenns of
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radiation carcinogenesis. Although the results of the two models are very similar in their
risk estimates, their biological interpretations are quite different. It has been generally
accepted that most of the biological consequences of ionizing radiation are due to the
interaction with the DNA producing changes in the replication and repair (UNSCEAR
2000). These changes are know to take place immediately following exposure and can
affect the initiation mechanism. The mechanism of promotion is an increase in the growth
imbalance during the time of exposure. This would mean that the radiation would induce
a rapid increase in the replication rate ([3) or decrease in the differentiation rate (b), which
is not biologically plausible during the brief exposure periods.

There are several

hypotheses on how radiation could affect promotion, such as negative selection (Mitchel
and Trivedi 1992), genomic instability (Little 1998;Wright 1998;Kadhim et al. 2001), and
bystander effect (Little and Wakeford 2001) - all of which would explain how a brief
exposure could result in lasting effect of the radiation (Little 2000).
From the results presented here, we see that at low doses, the Cox proportional
hazards model and the two-stage clonal expansion model (although from completely
different

theoretical

backgrounds

and

likelihood

descriptions of this data and estimated risk.

equations)

resulted

in

similar

This is because when IOg(J.!I) is the only

parameter with a slope coefficient ( b), the two-stage model satisfies the proportional
hazards model. The difference is in the interpretation of the models and their parameters
and baseline hazard estimation process. The Cox proportional hazards model does not
specify the baseline hazard function while in the two-stage model the baseline hazard is a
function of the constant terms of the parameter estimates, giving biological meaning to
the baseline hazard.
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CONCLUSION:
The main conclusion that can be drawn from these analyses is that the empirical
and biologically based dose response models resulted in very similar descriptions of the
low dose data.

The two-stage clonal expansion model with J.ll dependent on dose

satisfies the proportional hazards assumptions. Therefore the main difference in the two
models is how the background hazard is calculated and the interpretation of the
parameters, the empirical values results in a description of the dose effect while the twostage model allows inferences to be drawn about the background hazards and parameter
estimates that relate to the stage of carcinogenesis affected by dose.
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APPENDIX:

Two-stage Model Estimation Methods
Let Xo denote the number of normal susceptible cells in Figure 1. Xo is assumed
large and constant in the study period and J..ll=UXO, where u denotes the first initiation

rate per unit time per cell from the nonnal to intennediate cell. The survivor function

Set), or the probability of no tumor appearance up to time t, is given by
S(t)=exp {-A(t)}
where
J-ll {t(R+P-8- J1 2) 1 R-(f3- 8 -J.l2)+(R+f3-<5-J.lZ)e-Rt}
t = + og-----~---------:::..-~~
A()
~
2
2R

[A.I]

with

(Moolgavkar I 986;Kopp-Schneider et al. 1994). The three parameters

are identifiable, and the 0/, a net-proliferation rate, and p, an overall mutation rate, are
discussed in applications (Moolgavkar et al. 1999;Heidenreich et al. 1997a). However,
the complicated fonn of [A.I] often results in numerical problems in detennining the
precise MLE of the parameters.

Thus, Leenhouts et al set ()=Q in [A. 1] that results in

A'" ,f.l2. . ,u5:=0)= J.t;*
A( t, J..lI., ,t--J
~

[A*
1 {J.!; + ~., exp{(13'
" + f-l~) }}]
I-' t + og
*
*
f3

[A.2]

+f.12
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To distinguish between the parameters assuming 8=0 and the original parameters,

J.l: ,J3 '" and Jl;

are used in [A.2] (Leenhouts 1999). Leenhouts et al (1999) regard f3'" as

a net-proliferation rate.
Nakamura and Hoel (unpublished paper) obtain the following exact relationships
...

'V ==

R"'·
p - Jl2'

P=

... '"
}ll Jl z

'

and 11

]..11

= ~*

[A.3]

J3

Thus, MLE of the parameters 'V, p and 11 can be obtained from those of

I-l; ,f3 '" and 11;

using the simple transformation. Since Jl; is usually much smaller than ~*; 'If == ~*
should approximately hold.
Briefly, advantage of using [A.2] over the original [A. I ] is that appropriate initial
trial values may be obtained from two-dimensional grid tables and the iteration searching
for the MLE converges even in the method based on [A. I] fails to converge. More
detailed comparison between [A.1] and [A.2] is dealt with in Nakamura and Hoel
(unpublished paper).
Since the parameters take only positive values, we applied a log-linear model for
each parameter,
logeS)

=

a+bDose

[A.4]

where Dose denotes the exposure doses and a and b denote a constant tenn and a slope
coefficient, respectively. As for the overall mutation rate p,
log(p)

=

logXovJ-l2 = a+bDose.

Since Xo is constant independent of Dose, we have
log(VJ.12)

= a-IogXo+bDose.

That is, the slope coefficient b implies the effect of Dose on the over all mutation rate per

- 78 -

6.2 Comparison of Two Models of Risk Estimation: Part I
unit time per cell, VJl2, independent of the number of normal cells Xo. The unit time is

day, and the target tissue is whole body in the radiation data.
The model with only a constant term a for each of the three parameters J..lI,

f3 and

J..l2 is referred to as base model. The base model is independent of the exposure dose.
We obtained the significance of the slope term b for each parameter based on the
likelihood ratio test, relative to the base model, in a stepwise manner. It is
straightforward that the model with 109(J.!l)
log(~)

=

a+bDose, but no slope other terms (for

and log(J.!2)) satisfies the proportional hazards assumption.
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6.3 Comparison of Two Models of Risk Estimation: Part II

ABSTRACT:
The analyses in this paper are based on an expanded subset of the experimental
mortality data used in Part 1. The data comes from experiments using male and female
B6CF 1 mice, conducted at the Argonne National Laboratory, to study the effects of
exposure to whole-body irradiation to assess the shape of the dose response curve and the
effects of dose fractionation. The mice were grouped based on their sex, exposure pattern
(single exposure or 60 once-weekly exposures) and total accumulated dose of exposure
with doses ranging from 0 cGy to 1839 cGy for gamma exposure and 0 cGy to 226 cGy
for neutrons. The two-stage model and the Cox proportional hazards model are used to
compare the results of an empirical model with a model based on biological information
on the carcinogenesis process. Both the neutron and gamma dose response curves appear
linear at the lower doses (less than 30-40 cGy), before the nonlinearities become evident.
The findings suggest a reduction in the effectiveness of gamma irradiation with
fractionation, while the effectiveness of neutrons increases with fractionation.
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INTRODUCTION:
The previous paper (Part I) used a subset of the Argonne National Laboratory
(ANL) experimental mortality data of B6CF 1 mice exposed to external whole body
radiation with doses of gamma rays less than 300 cGy and fission neutron less than 30
cGy. In the current analysis, the data set is expanded to include high doses with dose
fractionation. The dose response curves are examined for the entire dose range (86 cGy 1839 cGy gamma and 1 cGy -226 cGy neutron exposure) and the low dose region is
compared with the results from the restricted data used in Part I.

To enable the

comparison of the different models, exposure patterns, and cancer types, the various
populations were truncated at a date when mice were still alive in all exposure groups,
which in this study included higher doses; therefore, the survival times are censored at
850 days (approximately 28 months) from the date of initial exposure instead of three
years as in Part I.

MATERIALS AND METHODS:
The material and methods used in this paper are described in detail in the previous
paper. Below is a brief description of the data and statistical methods.
The data used in these analyses is from the database compiled on the response of
male and female B6CF. mice to external whole body gamma, neutron, or sham
irradiation from the Biological and Medical Research Division at ANL (Grahn et al.
1995). The same data set (macroscopic data), exposure patterns (single exposure and 60
once-weekly exposure) and diagnosis classification (caused or contributed to death) were
investigated. A summary of the number of mice, their mean survival time, and the cases
of cancer for each dose group and exposure pattern is given in Table 1.

- 89-

6.3 Comparison of Two Models of Risk Estimation: Part II
Table 1 - Summary of the mice included in the analyses: Exposure pattern, Dose (cGy), Number of
mice, Mean age at death (± SE), Number of cases of solid tumors and lymphoreticular tumors
(percent).

Exposure

Pattern

Dose

a

0
Single
Gamma
Exposure

60 OnceWeekly
Gamma
Exposure

Single
Neutron
Exposure

60 OnceWeekly
Neutron
Exposure

86
137
198
257
400
546
756
0
100
200
300
450
600
1839
0
1
2
5
9
19
38
75
151
226
0
2
8
14
22
31
41
151

Number
of Mice
713
571
150
308
179
117
118
184
858
562
164
76

82
80
139
1725
661
411
312
230
780
142
185
117
187
705
520
204
219
225
135
76
152

MAD b
(+SE)
967.76 (+ 7)
940.95 (+ 8)
947.18 (±17)
923.68 (±11)
837.67 (±14)
864.03 (±17)
758.68 (±21)
593.42 (± 9)
990.01 (+ 7)
979.45 (± 7)
967.52 (±13)
924.26 (±21)
906.99 (±20)
908.15 (±20)
757.01 (±12)
971.39 (+ 5)
987.82 (+ 8)
973.04 (+ 9)
949.01 (+12)
931.75 (+13)
892.80 (± 7)
869.21 (±16)
788.67 (±14)
759.60 (±17)
697.38 (±13)
991.22 (± 7)
986.84 (± 8)
975.03 (±11)
924.02 (±11)
912.86 (±11)
905.47 (±14)
837.08 (±18)
742.46 (± 9)

Cancer Cases (Percent)
ST C
LRT d
209 (29)
326 (46)
287 (50)
157 (27)
71 (47)
43 (29)
150 (49)
112 (36)
77 (43)
61 (34)
49 (42)
38 (33)
34 (29)
40 (34)
31 (17)
60 (33)
351 (41)
385 (45)
233 (42)
275 (49)
67 (41)
72 (44)
38 (50)
30 (40)
31 (38)
39 (48)
40 (50)
33 (41)
52 (37)
50 (36)
499 (29)
741 (43)
320 (48)
181 (28)
124 (30)
190 (46)
120 (39)
102 (33)
77 (34)
83 (36)
276 (35)
296 (38)
69 (49)
45 (32)
47 (25)
63 (34)
53 (45)
28 (24)
35 (19)
54 (29)
187 (27)
399 (57)
295 (57)
134 (26)
115 (56)
58 (28)
71 (32)
110 (50)
128 (57)
65 (29)
64 (47)
45 (33)
29 (38)
32 (42)
41 (27)
68 (45)

ab-

Total accumulated dose measured in cGy
Mean age at death (MAD) given in days plus or minus the standard error (± SE)
c- Solid Tumors (ST)
d- L ymphoreticular Tumors (LRT)
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Statistical Methods

The investigation consists of the same basic approach to analyze the dose
response of three different cancer endpoints and compare the results as were used in
Part 1. Of interest in these analyses are primary tumor, lymphoreticular tumor, and solid
tumor - where primary tumor is the equivalent to "all cancer endpoints" and can be subgrouped into lymphoreticular ("all leukemia and lymphoma") and solid ("all cancers
other than leukemia and lymphoma") tumors.
The Cox proportional hazards (Cox 1972) model was used to investigate the
empirical relationship between dose and cancer. Four functions were evaluated for the
parametric form of dose to be used in the model; linear dose (D = dose), quadratic dose

linear-quadratic

CD

dose

and

log-linear

dose

== log [dose ]). The two-stage clonal expansion model parameters (8) were adjusted

to allow for a quadratic term before the log-linear transformation is applied to the
parameters
D2
log(8) == a + ho D+ hi 100

where D is the total accumulated gamma or neutron dose, a is a constant term, and b o
and b I are regression coefficients (Moolgavkar 1986).
The relative biological effectiveness (RBE) and dose rate effectiveness factor
(DREF) are dose weighting factors used to describe the differences in biological effect
for radiation qualities and dose rates.

They are calculated based on the initial slope

estimates, which for the non-linear and computed from the dose response curves
(Committee on the Biological Effects of Ionizing Radiation NRC 1990).

- 91 -

6.3 Comparison of Two Models of Risk Estimation: Part II

RESULTS:
To determine the function of dose to be used for each cancer type and exposure
pattern the Akaike's information criterion (AIC) scores (Aka ike 1976) were evaluated for
each and are presented in Table 2, with the lowest Ale score marked in boldface. We see
that the linear function of dose is the best fitting model for gamma exposure irrespective
of the cancer endpoint, while the linear-quadratic fits better for neutron irradiation.

The

only example where this does not hold true is for lymphoreticular tumors following acute
neutron exposure, where the linear model is slightly better, but not significantly different
from the linear-quadratic function.

Therefore when comparing the results with the two-

stage model the linear fonn is used for gamma exposure and the linear-quadratic [onn is

used for the neutron exposure.
Table 2 - Akaike Information Criterion (AIC) scores for the Cox proportional hazards model for each
cancer endpoint examined. The four functional forms of dose evaluated are the Linear (L), Quadratic (Q),
Linear-Quadratic (L-Q), and Log-Linear (L-L) functions of dose for each exposure pattern

Radiation
Exposure
Quality
Pattern
Primary Tumors
Gamma
Neutron

Single
Fractionated
Single
Fractionated

Ale Score
L
15028.68
11904.19
29306.62
14122.37

Q

15035.24
11914.53
29367.03
14155.58

a

L-Q
15028.76
11905.35

29268.34
14106~38

L-L
15106.02
11971.22
29279.31
14147.58

Lymph ore ticular
Tumors
Gamma
Neutron

Single
Fractionated
Single
Fractionated

5992.56
6084.90
16361.78
9184.90

6001.42
6091.28
16368.85
9195.69

5993.73
6086.12
16362.97

9006.17
5825.14
12983.81
4932.34

9005.18
5822.95

9178.91

6076.81
6121.56
16369.14
9184.19

Solid Tumors
Gamma
Neutron

Single
Fractionated
Single
Fractionated

9003.20
5821.11
12917.45
4907.53

12858.12
4893.50

9012.18
5851.47
12925.62
4927.85

a The smallest AIC Score represent the form of the model that best fits the data and is represented in bold
face.
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Radiation can affect the initiation rate, promotion rate, progression rate, or any
combination of these three rates in a linear, quadratic, or linear-quadratic manner.
Therefore, there are six different dose related parameters to consider in selecting the
optimal model.

To determine which of the parameters to include in our model, a

stepwise selection procedure was performed in which we found the best model based on
the log likelihood at each level of parameters, and then performed likelihood ratio tests to
see if the additional parameter significantly improved the fit of the model.
The models that describe the entire dose range are more complicated, and in most
cases, requiring more parameters (quadratic terms) to describe the data than was the case
when only low doses were considered in the model (Part I). The fractionated gamma
exposure the models were an exception, they were best described by a linear promotion
model

(~

is the only dose dependent parameter included in the model).

For most of the

other exposure patterns and cancer endpoints the model suggests that there are both
initiation and promotion effects in the radiation induced carcinogenesis process.
The single exposure patterns all have a positive initiation parameter and a
negative promotion parameter, indicating an increasing initiation and decreasing
promotion with increasing dose; the models for fractionated exposure patterns have a
positive promotion parameter.

The neutron exposure models, both the acute and

fractionated patterns, have a negative quadratic parameter estimates that causes a
downward curve in the dose response at higher doses, similar to a negative quadratic tenn
in the Cox linear-quadratic model.
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Table 3 - Parameter Estimates for the two-stage clonal expansion model for each exposure pattern (Exp) and dose range examined.

ExpU

G1

G60
N1

N6D

Cancer

Pr_T
Lr_T
S T
Pr_T
Lr_T
S_T
Pr_T
Lr_T
S_T
Pr_T
Lr_T
S_T

b

a

'"

-4.8929
-5.2876
-5.6721
-4.6695
-5.3706
-5.3483
-4.6528
-5.4542
-4.9557
-4.6801
-5.2419
-5.4325

IOg(J.l1 *)
bo
0.00152

--

bI

a

0.00043
0.00005

-4.8137
-4.8130
-4.6858
-4.7387
-4.7312
-4.7485

0.00280

--

--

--

--

--

-0.04920
0.03107
0.02547
0.00333
-0.00585

--0.0055
-0.0071
-0.0082

-4.8684
-4.7575
-4.9682
-4.7372

---

-4.6491

--

-4.8658

log «(3*)
bo
0.00031
--

-0.00050
0.00022
0.00023
0.00021
-0.00256
-0.00600

-0.00612
0.00545
0.00815

log (J..L2*)
bo

b1

a

-0.00021
-0.00023

-12.0559
-13.0443
-12.0836
-12.7101
-12.7190
-12.6992
-12.2134
-12.3611
-12.5299
-12.8313
-13.0251
-12.7533

---

---

----0.0027
-0.0024

-0.0036

hI

--

--

--

--

-- ----

--

--

--

--

-0.0251
--

--

--

--

--

--

--

-- ---

--

I

Exposure Patterns (Exp) are Gamma Single (01), Gamma Fractionated (060), Neutron Single (Nl) and Neutron Fractionated (N60).
Cancer types are Primary tumor (Pr_T), Lymphoreticular tumor (Lr~T) and Solid tumor (S~T)
2
'* Each parameter is modeled as logeS) = a + baD + b 1 (D /lOO). (--) value indicates that the parameter was not included in the model.

a

h
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Plots of the log risk versus total accumulated dose are used to depict the shape of
the dose response curve for the each cancer type. In Figure 1, we examine the primary
tumor dose-response curve for each exposure pattern.

The Cox proportional hazards

model (-) estimates the relative risk, while the two-stage model (---) estimates the
absolute risk. Therefore., for comparison purposes, without affecting the meaning of the
curves, the relative risk curves are adjusted to the absolute risk for the control group
(dose

=

0). The Kaplan-Meier observed risk ( • ) and the 95% confidence interval are

plotted for each dose group as a reference. Figures 2 and 3 are similar plots for the cancer
endpoints lymphoreticular tumors (Figure 2) and solid tumors (Figure 3).
The neutron dose response curves (Figures C and D) indicate that at doses
between 40 and 50 cGy, the neutron dose response curve starts to bend downward the
effect of the negative quadratic term in the models, as described above. The dose effect
of a single exposure to neutrons is less noticeable for lymphoreticular tumor (Figure 2C),
the slope is not as steep and only the two-stage model indicates a bend, but not until
higher doses (80 to 90 cGy); the Cox proportional hazard model is linear. When the
doses were restricted to the low dose range

«30 cGy), the dose effect for

lymphoreticular tumors following an acute neutron exposure was not statistically
significant (p=O.24). The dose response curve is shown in Figure 4.
In Figure 5 the low dose region of the primary tumor dose response curves from
this paper (entire dose range) are plotted against the estimates from the low doses
(ganuna <300 cGy and neutron <30 cGy) in Part I. The results for the entire dose range
are given in red, while the low dose range are denoted in blue.
similar, their interpretations can be different.

Although they look

In comparing gamma single to gamma 60
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once-weekly exposures (Figures 5A and 5B) both dose ranges indicate a reduction in the
effectiveness due to fractionation, but for neutron exposure (Figures 5C and 5D) the
entire dose range and low dose range result in disparate descriptions on effects of
fractionation.

There is an indication of an increased effect of fractionation when the

entire dose range is included in the analysis, while there is no noticeable affect of
fractionation when the analysis is restricted to the lower doses.
The RBE estimates and standard errors (Table 5) for these analyses, as in Part I,
are for the purposes of comparing the Cox proportional hazard and two-stage models,
because they are not adjusted for gender. The two models indicate similar patterns in the
RBE values, with values ranging from 1.41 to 23.77 for acute exposures and 24.98 to
46.35 in the case of fractionated exposures. This increase in the RBE values with
fractionated exposures is largely due to the reduced effectiveness of gamma with
increased fractionation. These values are consistent with values obtained from previous
studies, which have ranged from 2 to 100 depending on dose, dose-rate, energy, cell or
tissue culture, and cancer type. As seen in previous studies life shortening studies the
RBE for lymphoreticular tumors are generally lower than some subtypes of solid tumors
and the values for acute exposure are less than fractionated exposures due to the change
in effectiveness with fractionation (Carnes et al. 1989).

- 96-

6.3 Comparison of Two Models of Risk Estimation: Part II
Table 4 - Estimates of the neutron relative biological effectiveness (RBE) and standard error for
primary, Iymphoreticular, and solid tumors for each model and exposure pattern

Model
CPH
TSM

Exposure
Pattern
Single
Fractionated
Single
Fractionated

Primary Tumor
RBE
SE

8.52
34.15
7.06
33.9

1.02
5.38
0.77
4.01

Lymphoreticular
SE
RBE

1.49
24.98
1.41
25.02

0.25
6.22
0.18
5.26

Solid Tumor
RBE
SE

22.46
46.35

23.77
43.95

4.66
10.35
3.90
8.52

The models are the Cox proportional hazards model (CPH), the piece-wise linear Cox model (PWC) and
the two-stage model (TSM).

In Table 5, the dose rate effectiveness factors for gamma and neutron irradiation
are given for each cancer endpoint investigated. In general, the two-stage model and Cox
proportional hazards model give similar results for gamma and neutron DREF for each of
the cancer sites.

Fractionation reduces the effectiveness of gamma exposure, but

increases the effectiveness of neutron exposure similar to the finding from previous
studies on life shortening (Carnes et al. 1989), tumor mortality (Grahn et al. 1986), and
neoplastic transfonnations (Hill et a1. 1985).

When only low doses were used in the

analysis (Part I) there was no notable difference between the effectiveness of single and
fractionation neutron exposure. The DREF value estimated by the two-stage model for
lymphoreticular tumors is larger than the estimate based on the Cox proportional hazards
model. This is due to the curvelinear nature of the two-stage model (Figure 2A).
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Table 5 -Estimates of the dose rate effectiveness factor (DREF) and the Upper (U) and Lower (L)
standard error for primary, lympboreticular, and solid tumors for each model and radiation quality

Model
CPH
TSM

Radiation
Quality
Gamma
Neutron
Gamma
Neutron

Primary Tumor
DREF
(U, L)
2.53

0.64
2.85
0.64

(2.27,2.83)
(0.54,0.75)
(2.59,3.14)
(0.55,0.74)

Lymphoreticular
DREF

(U, L)

3.65
0.22

(3.19,4.15)
(0.17,0.30)
(5.33,6.22)
(0.25,0.35)

5.76
0.29

Solid Tumor
DREF
1.53
0.65
1.22
0.68

(U, L)
(1.23,1.95)
(0.51,0.82)
(1.03,1.43)
(0.56,0.80)

The models are the Cox proportional hazards model (CPH), the two-stage model (TSM)
(U,L) - are the upper and lower values for one standard error from the estimate.

The risk estimates for primary tumors, lymphoreticular tumors and solid tumors
are given in Table 6, as well as the risk estimates for primary tumors from Part I. The
most notable discrepancy in the risk estimates is for the risk of lymphoreticular tumors
from an acute exposure to gamma irradiation, where the two-stage model estimates a 70

% larger relative risk at 100 cGy (1 Gy) exposure. This is due to the curvilinear nature
of the two-stage model dose-response, at 450 cGy the results are approximately reversed
and the Cox model estimates a 70% larger relative risk than the two-stage model.
The risk estimates indicate that there is very little risk from highly fractionated
gamma exposures, which is agrees with the finding from the Canadian fluoroscopy study
for lung cancer mortality (Howe 1995). This is interesting because the majority of the
solid tumors in the JANUS data are lung cancers.

The relative risk estimates based on

the mortality studies of the atomic bomb survivors (Pierce et a1. 1996) are risk estimates
for an acute exposure to a combination of neutron and gamma irradiation, but at doses of
1 Gy the exposure is predominantly gamma rays. The estimated relative risk by gender
for solid tumors was 1.17 (male) and 1.44

(female)~

these values are comparable to the

ganuna single exposure in our study (which are male mice).
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Table 6 - Relative Risk estimates for 100 cGy gamma and 10 cOy neutron radiation exposure for the Cox
proportional hazards model (CPR), two-stage clonal expansion model (TSM) and the piece-wise linear Cox
model (PWM) for primary tumors, lymphoreticular tumors and solid tumors

Exposure

Pattern
Gamma
Single
Gamma
Fractionated
Neutron
Single
Neutron
Fractionated

Model

CPH
TSM
PWM

CPH
PWM

CPH
TSM
PWM

CPH
TSM

Relative Risk Estimate
Primary (Low Dose) Lymphoreticular

1.21
1.26
1.19
1.08
1.10
1.12
1.19
1.25
1.29
1.32

1.07
1.07

Solid
1.12
1.11
N/A
1.08
1.09
1.27
1.28

N/A
1.21
1.26

2.01
1.46
1.46

(1.20)

1.33

(1.22)

1.57
1.13
1.08

(1.13)
(1.12)
(1.26)
(1.26)
(1.28)
(1.27)

1.10

Relative risk estimates for primary tumor are given as the relative risk for all doses with the relative risk
estimates from when only low doses are included in the analysis in parentheses

DISCUSSION:
We see that in most cases the Cox proportional hazards model and two-stage

clonal expansion model result in similar dose response curves, risk estimates, and
weighting factors to describe the effect of radiation qualities and dose rates. But there are
advantages of using a biologically based model, like the two-stage model such as - they
necessitate a better understanding of the disease process being studied, the parameter
estimates have biological interpretations, and they increase the credibility of the risk
assessment (Goddard and Krewski 1995).
It has been generally accepted that the majority of the biological consequences
associated with ionizing radiation are due to a direct interaction with DNA, altering the
replication and repair process. There are many types of radiation induced DNA lesions,
but misrepaired double strand breaks are considered the essential lesion in the induction
of both chromosomal abnormalities and gene mutations (Ward 1995).

Of these

chromosomal abnormalities and gene mutations it has been suggested that the
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inactivation of a tumor suppressor gene, by loss of heterozygosity, is most likely to be the
initiating event in radiation carcinogenesis (Little 2000).
For single exposures to gamma and neutron irradiation we see a positive initiation

effect combined with a negative promotion effect. It has been hypothesized that in the
presence of a strong initiator, such as radiation, an increase in apoptosis would
accompany the increase in initiated cells due to initiation, in order to keep the number of
intennediate cells in check (Nakamura and Hoel 2002).
The results for most cancer types and exposure patterns indicate that part of the
risk from exposure to radiation is its effect on the net proliferation rate, promotion effect.
Although it has been suggested that it would not be biologically plausible for a brief
exposure to induce the increased growth imbalance necessary to see a promotion effect, it
has been proposed that radiation inactivates or kills cells, which are then replaced by the
division of neighboring cells. Since initiated cells have a growth advantage over nonnal
cells they fill the void faster than normal cells (Heidenreich and Hoogenveen 2001).
The brief exposure periods experienced by the animals in the JANUS program are
quite

different

from

the

extended

exposure

periods

used

to

define

chemical

carcinogenesis. Therefore a biological rationalization is needed to explain how radiation
can cause a change in the parameter values that is constant throughout the entire study
period. Recent studies have indicated that radiation may induce some indirect genetic
consequences in cells that themselves do not receive direct nuclear radiation. Currently
three areas of research into this phenomenon are: radiation induced genomic instability,
bystander effect, and cytoplasmic irradiation.

The tenn genetic instability is used to

describe a transfonnation, characteristic of a mutagenic event, which may occur in the
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progeny of an irradiated cell, even after many generations of cell replication. This lead to
the hypothesis that radiation induces a transmissible genetic instability that has the effect
of enhancing the rate of transfonnation in the descendents of an irradiated cell (Little
2000;Mothersill and Seymour 1998).

Bystander effect implies that persistent, genetic

alterations can occur in nonirradiated cells due to damaged signals transmitted by
neighboring irradiated cells (Little 2000). Furthennore studies have been demonstrated
links between a bystander effect and genomic instability; chromosomal instability has
been detected in the progeny of nonirradiated cells (Watson et al. 2000). Cytoplasmic
irradiation has been shown to induce a significant increase in the spontaneous mutation
frequency, while having little effect on cell survivaL These phenomenons could play
important roles in the carcinogenic effects at lower doses, where fewer cells are in direct
contact with the radiation (Lewis et al. 2001) and would increase the probability that a
cell could accumulate the mutational events necessary to give rise to a malignant tumor
(Kadhim et al. 2001 ;Little 1998). These findings indicates that the carcinogenic effects
of ionizing radiation is not restricted to the direct interaction with DNA and suggest that
radiation could act as a chronic exposure.
There is a noticeable downward curvature at higher doses of the dose response
curves for neutron exposure.

This type of curvature has been seen in this and other

mouse data for life shortening effects (Storer and Fry 1995) as well as in the Atomic
bomb survivorship data (Shimizu et a1. 1990). Cell killing is the likely explanation of the
downward curvature at higher doses.

It has been shown that a linear model with an

exponential cell killing tenn can be used to describe a linear-quadratic model, where the
negative quadratic term indicates cell killing. Although this cannot be estimated directly
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by the Cox proportional hazards model, it provides an adequate fit to the Cox dose
response curve (Figure 6). The two-stage model does not include a parameter for cell
killing and therefore it is not possible to separate the effects of cell killing from the other
effects estimated in the model.
Inferences made about the mechanism of actions of an agent based on these
analyses must be taken cautiously. Because although the

two~stage

model is useful in

generating hypotheses about the underlying mechanism of carcinogenesis, it has been
shown that tumor incidence data does may not have the power to distinguish between
initiating and promoting effects (Portier 1987).

CONCLUSION:
These analyses suggest that the empirical and biologically based models result in
similar, linear descriptions of the low dose region of the dose response curve.

The

difference in the two models is seen for single exposures to gamma irradiation with
respect to lymphoreticular tumors in which the two-stage clonal expansion models
predicts a steeper initial slope of the dose response curve, and therefore a higher DREF
and risk of cancer than the Cox proportional hazards model. The parameterization of the
two-stage model suggests both the initiation and promotion effects are involved in
radiation induced carcinogenesis.
The dose range used in the analysis affected the RBE and DREF values for both
models, but did not have much effect on the estimates of risk.

When the entire dose

range is analyzed the RBE for acute exposures is slightly lower than for the low dose data
while the fractionated exposures results in high RBE values. These values are typical of
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the RBE values found in other studies, which have ranged from 2 to 100. The results
suggest that neutrons exposure appears to have more effect on solid tumors than gamma
irradiation (RBE approximately 3 times higher for solid tumors than for all cancers
combined) and a very small effect on lymphoreticular cancers (RBE almost 1.5). The
DREF values indicate a reduction in the effectiveness of gamma irradiation with
fractionation, while the neutron indicated an increased effectiveness when the entire dose
range is analyzed.

The resulting nonlinearities in the dose response curve become evident at higher
doses as has been seen in life shortening studies. In particular the dose response curves
for the different cancer endpoints following neutron exposure bend downward at higher
doses, possibly indicating a cell killing effect.

To determine the best approaches to

radiation protection, the issue of non-linearity in the dose response curve will have to be
settled based on a better understanding of the radiobiology associated with radiation
.

.

carclnogeneSIS.
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7. Summary

7. SUMMARY
The purpose of this research was to evaluate the low dose region of the dose
response curve for cancer risks from ionizing radiation. Although this has been examined
and reported in the past, errors in the dose estimates have been shown to alter the shape
of the dose response curve at low doses. In the analyses of the atomic bomb data the
appropriate corrections were made to the dose estimates and the models fit to the
corrected dose to see if previous findings indicating non-linearities at low doses were still
found or if they were simply an artifact of the errors in the dose.
In Paper I a threshold was included in the model, as a surrogate for non-linearity.
The threshold model was found to significantly improve the fit of the solid tumor
incidence model when the doses are adjusted for uncertainty and systematic neutron
error, and the neutron RBE is considered dose-dependent.

The non-linearity that was

seen previously in the uncorrected leukemia incidence data was still present after the dose
adjustments, therefore providing further support for the use of a non-linear model at low
doses. The mortality data did not indicate a significant improvement in the fit of the data
although, the threshold and no threshold models were indistinguishable at lower doses.
Only the solid tumor incidence data did not indicate an improvement with the addition of
a threshold, similar to the results of the uncorrected doses.
Papers II and III look at the ANL mouse data to gain insight into the modifying
effect of fractionation on gamma and neutron exposures.

In Paper II only the lower

doses were included in the analyses, and resulted in a linear models for both radiation
qualities, independent of the exposure pattern. The two-stage model was best fit with the

J..ll model in which initiation was the only stage dependent on dose. Both models, the Cox
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proportional hazards model and the two-stage clonal expansion model resulted in the
same description of the data, with the two-stage model reducing to a proportional hazards
description of the data when J.lI is the only dose dependent parameter. At low and high
doses

fractionation

reduced the

effectiveness

of gamma

irradiation while,

the

fractionation of neutron produced results that were dependent on the dose range being
examined. In the analyses of the data restricted to low neutron doses there was no change

in the effectiveness of neutrons due to fractionation but when the entire dose range was
included the results indicated that there was an increase in their effectiveness.

The

models that best describe the data for the entire dose range are much more complicated
than those for the low doses. The Cox proportional hazards model fit the linear-quadratic
tenn to the neutron exposures and the two-stage model indicates that both the initiation
and promotion effects are needed to describe the carcinogenesis process following
ionizing radiation exposure.
It remains to be detennined how many of the recent advancements in the
understanding of radiation biology are going to affect the issue of non-linearity in the low
dose region of the dose response curve. The issue will in the future influence the
approached to radiation protection.

Limitations
•

A-bomb Data
•

Data available is grouped by city, sex, dose, age at exposure and calendar
time; therefore we are correcting the average gamma and neutron dose and
calculating the dose-dependent RBE based and the corrected average doses. If
the corrected average dose moves up into the next dose group then the entire
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group is moved up. As well, there is no variability associated with the
average dose.
•

The entire cohort is Japanese and exposed at one time. This reduces the
ability to extrapolate the results to other populations from different times.
Because there are genetic components of cancer risk, and cancer risk have
been shown to change over time.

•

There are uncertainties that are associated with the correction factors and
methods that cannot be separated.

•

JANUS Mouse Data
•

The study is retrospective therefore the data was collected with other studies
in mind and we are using it to explore the effects of fractionation at low doses.
Therefore we have to deal with the data that is available. There are not many
truly low doses available in the gamma exposures. In fact the lowest dose
available is 86 cGy for the single exposures and 100 cGy for the fractionated
exposures. This means that any non-linearity that may occur at smaller doses

(as seen in the A-bomb study at approximately 20 cSv) would be missed in
these analyses. As well, the doses available did not pennit us to explore the
effect of radiation quality within the same sex. The gamma exposures were
restricted to male mice and the neutron exposures were only female mice.
•

Could not look at possible trend with increasing fractionation because the 24
once-weekly exposure data did not contain data for low doses.

•

Inferences made about the mechanism of actions of an agent based on these
analyses must be taken cautiously. Because although the two-stage model is
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useful in generating hypotheses about the underlying mechanism of
carcinogenesis, it has been shown that tumor incidence data does may not
have the power to distinguish between initiating and promoting effects.

Future Work
•

A-bomb Data
•

Analysis with data on the neutron activation measurements for a more
accurate correction

•

Include Nagasaki to see if dose corrections for both cities bring the predictions
of risk inline with one another. (Includes collection of copper samples in
Nagasaki to allow for neutron activation measurements)

•
•

Use of individual data to for the dose corrections

Mouse Data
•

Apply models to a data set that included comparable doses for both sexes and
radiation qualities

•

Adjust the model to account for the fact that fractionated doses are distributed
over time.
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